<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00296504</url>
  </required_header>
  <id_info>
    <org_study_id>APV30005</org_study_id>
    <nct_id>NCT00296504</nct_id>
  </id_info>
  <brief_title>A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects</brief_title>
  <official_title>An Open-Label Phase III Study to Assess the Long Term Safety Profile of GW433908 Containing Regimens in HIV-1 Infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ViiV Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GW433908 (fosamprenavir; FPV)is a pro-drug of amprenavir (APV) which is more water soluble
      and can be formulated into a tablet with a reduced pill burden (four 700mg tablets of FPV
      versus sixteen 150mg capsules daily for APV. This study is designed to provide additional
      information on long term safety and tolerability of FPV containing regimens for those
      subjects who received FPV in previous GlaxoSmithKline studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ViiV Healthcare is the new sponsor of this study, and GlaxoSmithKline is in the process of
      updating systems to reflect the change in sponsorship.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Any Adverse Event (AE): Interim Analysis</measure>
    <time_frame>Baseline (Day 1) up to 31 January 2006 (up to Week 264)</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A list of all adverse events is reported in the &quot;Other (Non-Serious) Adverse Events&quot; section.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Any Adverse Event (AE): Final Analysis</measure>
    <time_frame>Post January 2006; for up to 241 weeks</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A list of all adverse events is reported in the &quot;Other (Non-Serious) Adverse Events&quot; section.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in the Indicated Clinical Chemistry Parameters at Weeks 48, 96, 120, 132, 168, 180, 204, and 216</measure>
    <time_frame>Baseline (Day 1) and Weeks 48, 96, 120, 132, 168, 180, 204, and 216</time_frame>
    <description>Fasting blood samples of participants were collected for the assessment of triglycerides (Tri.), cholesterol (Chol.), high density cholesterol (HDL), low density cholesterol (LDL), and fasting blood glucose (FBG). Change from Baseline at Weeks (W) 48, 96, 120, 132, 168, 180, 204, and 216 was calculated as the value at that particular week minus the value at Baseline (Day 1).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Values of the Indicated Clinical Chemistry Parameters at Weeks 120, 180, 204, 216, and 432</measure>
    <time_frame>Weeks 120, 180, 204, 216, and 432</time_frame>
    <description>Fasting blood samples of participants were collected for the assessment of triglycerides, cholesterol, high density cholesterol (HDL), low density cholesterol (LDL), and fasting blood glucose (FBG).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in the Total Cholesterol/HDL Ratio at Weeks 48, 120, 180, 204, and 216</measure>
    <time_frame>Baseline (Day 1) and Weeks 48, 120, 180, 204, and 216</time_frame>
    <description>blood samples of participants were collected for the assessment of the total cholesterol/HDL ratio. The ratio of total cholesterol/HDL was calculated by dividing the value of total cholesterol by the value of HDL. Change from Baseline at Weeks 48, 120, 180, 204, and 216 was calculated as the value at that particular week minus the value at Baseline (Day 1).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in the Total Cholesterol/HDL Ratio at Weeks 48, 96, 132, and 168</measure>
    <time_frame>Baseline (Day 1) and Weeks 48, 96, 132, and 168</time_frame>
    <description>Fasting blood samples of participants were collected for the assessment of the total cholesterol/HDL ratio. The ratio of total cholesterol/HDL was calculated by dividing the value of total cholesterol by the value of HDL. Change from Baseline at Weeks 48, 96, 132, and 168 was calculated as the value at that particular week minus the value at Baseline (Day 1).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Value of the Total Cholesterol/HDL Ratio at Weeks 120, 180, 204, 216, and 432</measure>
    <time_frame>Weeks 120, 180, 204, 216, and 432</time_frame>
    <description>Fasting blood samples of participants were collected for the assessment of the total cholesterol/HDL ratio. The ratio of total cholesterol/HDL was calculated by dividing the value of total cholesterol by the value of HDL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Aspartate Aminotransferase (AST), Alanine Transaminase (ALT), and Serum Lipase at Weeks 48, 120, 180, 204, and 216</measure>
    <time_frame>Baseline (Day 1) and Weeks 48, 120, 180, 204, and 216</time_frame>
    <description>Blood samples of participants were collected for the assessment of AST, ALT, and serum lipase. Change from Baseline at Weeks 48, 120, 180, 204, and 216 was calculated as the value at that particular week minus the value at Baseline (Day 1).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Aspartate Aminotransferase (AST), Alanine Transaminase (ALT), and Serum Lipase at Weeks 48, 96, 132, and 168</measure>
    <time_frame>Baseline (Day 1) and Weeks 48, 96, 132, and 168</time_frame>
    <description>Blood samples of participants were collected for the assessment of AST, ALT, and serum lipase. Change from Baseline at Weeks 48, 96, 132, and 168 was calculated as the value at that particular week minus the value at Baseline (Day 1).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Aspartate Aminotransferase (AST), Alanine Transaminase (ALT), and Serum Lipase Values at Weeks 120, 180, 204, 216, and 432</measure>
    <time_frame>Weeks 120, 180, 204, 216, and 432</time_frame>
    <description>Blood samples of participants were collected for the assessment of AST, ALT, and serum lipase.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) &lt;400 and &lt;50 Copies Per Milliliter at Baseline and Weeks 48, 120, 180, and 216 (MD=F and Observed)</measure>
    <time_frame>Baseline and Weeks 48, 120, 180, and 216</time_frame>
    <description>Blood samples of participants were collected for the assessment of HIV-1RNA copies in plasma. Viral load, measured in RNA copies per milliliter of plasma, is an efficacy measure for antiretroviral drugs. In the MD=F analysis, participants who had missing data at or had discontinued the study prior to a certain time point are classified as non-responders. In the observed analysis (OA), data are presented for the number of participants still enrolled in the study at a certain time point. Participants in the NFV populations had received antiretroviral therapy prior to Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Plasma HIV-1RNA &lt;400 and &lt;50 Copies Per Milliliter at Baseline and Weeks 12, 24, 48, 60, 96, and 132 (MD=F and Observed)</measure>
    <time_frame>Baseline and Weeks 12, 24, 48, 60, 96, and 132</time_frame>
    <description>Blood samples of participants were collected for the assessment of HIV-1RNA copies in plasma. Viral load, measured in RNA copies per milliliter of plasma, is an efficacy measure for antiretroviral drugs. In the MD=F analysis, participants who had missing data at or had discontinued the study prior to a certain time point are classified as non-responders. In the observed analysis (OA), data are presented for the number of participants still enrolled in the study at a certain time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Plasma HIV-1RNA &lt;50 Copies Per Milliliter at Baseline and Weeks 120, 180, 240, 300, 360, 420, and 432 (Observed)</measure>
    <time_frame>Baseline and Weeks 120, 180, 240, 300, 360, 420, and 432</time_frame>
    <description>Blood samples of participants were collected for the assessment of HIV-1RNA copies in plasma. Viral load, measured in RNA copies per milliliter of plasma,is an efficacy measure for antiretroviral drugs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cluster of Differentiation Antigen 4 (CD4+) Cell Count at Baseline and Weeks 48, 120, 168, 180, 204, and 216: Observed Analysis</measure>
    <time_frame>Baseline and Weeks 48, 120, 168, 180, 204, and 216</time_frame>
    <description>Blood samples of participants were collected for the assessment of CD4+ cell count. CD4+ cells are white blood cells that are important in fighting infection. HIV infects CD4+ cells, replicates in them, and destroys them. CD4+ cell count provides a measure of the status of the immune system and to what extent it is affected by HIV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cluster of Differentiation Antigen 4 (CD4+) Cell Count at Baseline and Weeks 24, 48, 96, 132, and 168: Observed Analysis</measure>
    <time_frame>Baseline and Weeks 24, 48, 96, 132, and 168</time_frame>
    <description>Blood samples of participants were collected for the assessment of CD4+ cell count. CD4+ cells are white blood cells that are important in fighting infection. HIV infects CD4+ cells, replicates in them, and destroys them. CD4+ cell count provides a measure of the status of the immune system and to what extent it is affected by HIV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Plasma HIV-1 RNA at Baseline and Weeks 24, 48, 72, 96, 120, 144, 168, 180, 204, and 216</measure>
    <time_frame>Baseline and Weeks 24, 48, 72, 96, 120, 144, 168, 180, 204, and 216</time_frame>
    <description>Blood samples of participants were collected for the assessment of plasma HIV-1 RNA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Plasma HIV-1 RNA at Baseline and Weeks 12, 24, 48, 72, 96, 132, and 168</measure>
    <time_frame>Baseline and Weeks 12, 24, 48, 72, 96, 132, and 168</time_frame>
    <description>Blood samples of participants were collected for the assessment of plasma HIV-1 RNA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Plasma HIV-1 RNA at Weeks 180, 240, 300, 360, 420, and 432</measure>
    <time_frame>Weeks 180, 240, 300, 360, 420, and 432</time_frame>
    <description>Blood samples of participants were collected for the assessment of plasma HIV-1 RNA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With HIV-1 Disease Progression to CDC Class C, or New CDC Class C or Death, From Baseline</measure>
    <time_frame>Baseline (Day 1) up to 31 January 2006 (up to Week 264)</time_frame>
    <description>The number of participants with progression of HIV-1 disease were assessed using the CDC classification of HIV-1: class A, asymptomatic or lymphadenopathy; class B: symptomatic, but not AIDS; class C, AIDS. A participant is considered to have had a disease progression if they report a CDC Class C event for the first time, if they report a new CDC Class C event, or if they experience any fatal adverse event during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Enrolled in Studies APV30001 and APV300002 With the Indicated HIV-associated Conditions</measure>
    <time_frame>Baseline (Day 1) up to 31 January 2006 (up to Week 264)</time_frame>
    <description>The number of participants with the indicated HIV-associated conditions were assessed, excluding recurrences.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Enrolled in Study APV30003 and Other Studies With the Indicated HIV-associated Conditions</measure>
    <time_frame>Baseline (Day 1) up to 31 January 2006 (up to Week 264)</time_frame>
    <description>The number of participants with the indicated HIV-associated conditions were assessed.</description>
  </secondary_outcome>
  <enrollment type="Actual">753</enrollment>
  <condition>Infection, Human Immunodeficiency Virus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fosamprenavir (GW433908)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ritonavir</intervention_name>
    <other_name>fosamprenavir (GW433908)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or non-pregnant/non-lactating females &gt;/=13 years of age (or &gt;/= 18 years of age
             according to local requirements).

          -  Received fosamprenavir through prior participation in APV20001, APV30002, APV30003 or
             PRO30017 or have participated in APV30001 or other studies as deemed appropriate by
             the project team.

        Exclusion Criteria:

          -  Permanent discontinuation of GW433908 in a previous study due to intolerance.

          -  An active CDC Class C Event.

          -  Any condition which, in the opinion of the investigator, would preclude a subject from
             participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>ViiV Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115-1931</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33145</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-1188</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <zip>13083970</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago</city>
        <state>Región Metro De Santiago</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Le Kremlin Bicêtre Cedex</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris Cedex 10</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris Cedex 20</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vandoeuvre Les Nancy Cedex</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Badajoz</city>
        <zip>6080</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Chile</country>
    <country>France</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Costa Rica</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Latvia</country>
    <country>Panama</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>South Africa</country>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2006</study_first_submitted>
  <study_first_submitted_qc>February 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2006</study_first_posted>
  <results_first_submitted>September 30, 2011</results_first_submitted>
  <results_first_submitted_qc>September 30, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 8, 2011</results_first_posted>
  <last_update_submitted>April 11, 2013</last_update_submitted>
  <last_update_submitted_qc>April 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antiretroviral therapy naive subjects</keyword>
  <keyword>fosamprenavir</keyword>
  <keyword>HIV-1</keyword>
  <keyword>protease inhibitor</keyword>
  <keyword>pro-drug</keyword>
  <keyword>antiretroviral therapy</keyword>
  <keyword>LEXIVA</keyword>
  <keyword>AGENERASE</keyword>
  <keyword>GW433908</keyword>
  <keyword>amprenavir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Fosamprenavir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>APV30005 enabled Human Immunodeficiency Virus (HIV)‐infected participants who had received a Fosamprenavir (FPV)‐containing or other regimen in a number of studies, including APV30001, APV30002, and APV30003, to receive FPV until 31 January 2006 (Interim Analysis) or until commercial supplies of FPV were available locally, whichever was later.</recruitment_details>
      <pre_assignment_details>Participants are divided into arms depending on the regimen they received in Studies APV30001, APV30002, and APV30003 or whether they were PI-naïve or PI‐experienced at the time they enrolled into other studies. For the final analysis, 111 participants are included who continued in APV30005 after 31 January 2006 until study completion.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>FPV Population (APV30001)</title>
          <description>Fosamprenavir (FPV) +/- ritonavir (RTV) + background regimen in participants who had received FPV in APV30001 (NCT00008554)</description>
        </group>
        <group group_id="P2">
          <title>NFV Population (APV30001)</title>
          <description>FPV +/- RTV + background regimen in participants who had received nelfinavir (NFV) in APV30001</description>
        </group>
        <group group_id="P3">
          <title>FPV Population (APV30002)</title>
          <description>FPV +/- RTV + background regimen in participants who had received FPV in APV30002 (NCT00009061)</description>
        </group>
        <group group_id="P4">
          <title>NFV Population (APV30002)</title>
          <description>FPV +/- RTV + background regimen in participants who had received NFV in APV30002</description>
        </group>
        <group group_id="P5">
          <title>FPV/RTV Once Daily (QD) Population (APV30003)</title>
          <description>FPV +/- RTV + background regimen in participants who had received FPV/RTV QD in APV30003 (no NCT number)</description>
        </group>
        <group group_id="P6">
          <title>FPV/RTV Twice Daily (BID) Population (APV30003)</title>
          <description>FPV +/- RTV + background regimen in participants who had received FPV/RTV BID in APV30003</description>
        </group>
        <group group_id="P7">
          <title>Protease Inhibitor (PI)-Naïve Population (Other Studies)</title>
          <description>FPV +/- RTV + background regimen in participants who were PI-naïve prior to enrollment in the parent study</description>
        </group>
        <group group_id="P8">
          <title>PI-Experienced Population (Other Studies)</title>
          <description>FPV +/- RTV + background regimen in participants who were PI-experienced prior to enrollment in the parent study</description>
        </group>
        <group group_id="P9">
          <title>Final Analysis Population (APV30005)</title>
          <description>FPV +/- RTV + background regimen in participants who remained in APV30005 after 31 January 2006</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Interim Analysis</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="119"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="221"/>
                <participants group_id="P4" count="54"/>
                <participants group_id="P5" count="73"/>
                <participants group_id="P6" count="78"/>
                <participants group_id="P7" count="104"/>
                <participants group_id="P8" count="86"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Ongoing</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="30"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="116"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="36"/>
                <participants group_id="P6" count="41"/>
                <participants group_id="P7" count="30"/>
                <participants group_id="P8" count="37"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="105"/>
                <participants group_id="P4" count="43"/>
                <participants group_id="P5" count="37"/>
                <participants group_id="P6" count="37"/>
                <participants group_id="P7" count="74"/>
                <participants group_id="P8" count="49"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="11"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clinical Progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient Viral Load Response</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="24"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient CD4 Response</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Switched to Commercially Available Drug</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Non-compliant</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Wanted to Become Pregnant</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>To Simplify Treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Had Problems with Alcohol</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Moved</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Was Incarcerated</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Resistance to FPV</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Principle Investigator Discretion</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Principle Investigator Terminated Study</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-adherence</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site Closing</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Personnel at Site</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed Schedule Date</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inclusion in Other Protocol</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Stopped</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician and Participant Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Stopped HIV Medications</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Ended</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Needed Interferon</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ongoing</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="30"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Final Analysis</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="111">Continued in study; commercial supplies of FPV were unavailable locally at end of Interim Analysis.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient Viral Load Response</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Tuberculosis</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Moved to Another Country</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor Adherence</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FPV Population (APV30001)</title>
          <description>FPV +/- RTV + background regimen in participants who had received FPV in APV30001 (NCT00008554)</description>
        </group>
        <group group_id="B2">
          <title>NFV Population (APV30001)</title>
          <description>FPV +/- RTV + background regimen in participants who had received NFV in APV30001</description>
        </group>
        <group group_id="B3">
          <title>FPV Population (APV30002)</title>
          <description>FPV +/- RTV + background regimen in participants who had received FPV in APV30002 (NCT00009061)</description>
        </group>
        <group group_id="B4">
          <title>NFV Population (APV30002)</title>
          <description>FPV +/- RTV + background regimen in participants who had received NFV in APV30002</description>
        </group>
        <group group_id="B5">
          <title>FPV/RTV QD Population (APV30003)</title>
          <description>FPV +/- RTV + background regimen in participants who had received FPV/RTV QD in APV30003 (no NCT number)</description>
        </group>
        <group group_id="B6">
          <title>FPV/RTV BID Population (APV30003)</title>
          <description>FPV +/- RTV + background regimen in participants who had received FPV/RTV BID in APV30003</description>
        </group>
        <group group_id="B7">
          <title>PI-Naïve Population (Other Studies)</title>
          <description>FPV +/- RTV + background regimen in participants who were PI-naïve prior to enrollment in the parent study</description>
        </group>
        <group group_id="B8">
          <title>PI-Experienced Population (Other Studies)</title>
          <description>FPV +/- RTV + background regimen in participants who were PI-experienced prior to enrollment in the parent study</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="119"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="221"/>
            <count group_id="B4" value="54"/>
            <count group_id="B5" value="73"/>
            <count group_id="B6" value="78"/>
            <count group_id="B7" value="104"/>
            <count group_id="B8" value="86"/>
            <count group_id="B9" value="753"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.3" lower_limit="17" upper_limit="70"/>
                    <measurement group_id="B2" value="35.8" lower_limit="22" upper_limit="54"/>
                    <measurement group_id="B3" value="37.7" lower_limit="19" upper_limit="69"/>
                    <measurement group_id="B4" value="36.2" lower_limit="26" upper_limit="63"/>
                    <measurement group_id="B5" value="41.9" lower_limit="27" upper_limit="58"/>
                    <measurement group_id="B6" value="42.3" lower_limit="24" upper_limit="71"/>
                    <measurement group_id="B7" value="39.3" lower_limit="21" upper_limit="75"/>
                    <measurement group_id="B8" value="40.2" lower_limit="19" upper_limit="60"/>
                    <measurement group_id="B9" value="38.7" lower_limit="17" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="24"/>
                    <measurement group_id="B8" value="22"/>
                    <measurement group_id="B9" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="158"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="64"/>
                    <measurement group_id="B6" value="66"/>
                    <measurement group_id="B7" value="80"/>
                    <measurement group_id="B8" value="64"/>
                    <measurement group_id="B9" value="555"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="109"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="59"/>
                    <measurement group_id="B6" value="56"/>
                    <measurement group_id="B7" value="44"/>
                    <measurement group_id="B8" value="77"/>
                    <measurement group_id="B9" value="394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="86"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="34"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="23"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other: Race Not Specified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Participants with the Indicated CDC Classification of HIV Infection</title>
          <description>The Centers for Disease Control and Prevention (CDC) 1993 classification system for HIV infection was based on three clinical categories (A, B, and C). Category A comprised asymptomatic acute or primary HIV infection or persistent generalized lymphadenopathy (lymphnode disease). Category B comprised symptomatic conditions not included in clinical categories A or C but attributed to a cell-mediated immunity defect or for which the clinical course or management was complicated by HIV infection. Category C comprised AIDS-defining conditions.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asymptomatic or lymphadenopathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="124"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="30"/>
                    <measurement group_id="B7" value="76"/>
                    <measurement group_id="B8" value="29"/>
                    <measurement group_id="B9" value="395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptomatic, not AIDS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="24"/>
                    <measurement group_id="B7" value="23"/>
                    <measurement group_id="B8" value="18"/>
                    <measurement group_id="B9" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acquired Immune Deficiency Syndrome (AIDS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="24"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="39"/>
                    <measurement group_id="B9" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Any Adverse Event (AE): Interim Analysis</title>
        <description>An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A list of all adverse events is reported in the &quot;Other (Non-Serious) Adverse Events&quot; section.</description>
        <time_frame>Baseline (Day 1) up to 31 January 2006 (up to Week 264)</time_frame>
        <population>All participants receiving at least one dose of FPV or FPV/RTV in Study APV30005.</population>
        <group_list>
          <group group_id="O1">
            <title>FPV Population (APV30001)</title>
            <description>FPV +/- RTV + background regimen in participants who had received FPV in APV30001 (NCT00008554)</description>
          </group>
          <group group_id="O2">
            <title>NFV Population (APV30001)</title>
            <description>FPV +/- RTV + background regimen in participants who had received NFV in APV30001</description>
          </group>
          <group group_id="O3">
            <title>FPV Population (APV30002)</title>
            <description>FPV +/- RTV + background regimen in participants who had received FPV in APV30002 (NCT00009061)</description>
          </group>
          <group group_id="O4">
            <title>NFV Population (APV30002)</title>
            <description>FPV +/- RTV + background regimen in participants who had received NFV in APV30002</description>
          </group>
          <group group_id="O5">
            <title>FPV/RTV QD Population (APV30003)</title>
            <description>FPV +/- RTV + background regimen in participants who had received FPV/RTV QD in APV30003 (no NCT number)</description>
          </group>
          <group group_id="O6">
            <title>FPV/RTV BID Population (APV30003)</title>
            <description>FPV +/- RTV + background regimen in participants who had received FPV/RTV BID in APV30003</description>
          </group>
          <group group_id="O7">
            <title>PI-Naïve Population (Other Studies)</title>
            <description>FPV +/- RTV + background regimen in participants who were PI-naïve prior to enrollment in the parent study</description>
          </group>
          <group group_id="O8">
            <title>PI-Experienced Population (Other Studies)</title>
            <description>FPV +/- RTV + background regimen in participants who were PI-experienced prior to enrollment in the parent study</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Adverse Event (AE): Interim Analysis</title>
          <description>An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A list of all adverse events is reported in the &quot;Other (Non-Serious) Adverse Events&quot; section.</description>
          <population>All participants receiving at least one dose of FPV or FPV/RTV in Study APV30005.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="221"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="73"/>
                <count group_id="O6" value="78"/>
                <count group_id="O7" value="104"/>
                <count group_id="O8" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="215"/>
                    <measurement group_id="O4" value="52"/>
                    <measurement group_id="O5" value="72"/>
                    <measurement group_id="O6" value="75"/>
                    <measurement group_id="O7" value="95"/>
                    <measurement group_id="O8" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Any Adverse Event (AE): Final Analysis</title>
        <description>An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A list of all adverse events is reported in the &quot;Other (Non-Serious) Adverse Events&quot; section.</description>
        <time_frame>Post January 2006; for up to 241 weeks</time_frame>
        <population>All participants who remained in the study after January 31, 2006.</population>
        <group_list>
          <group group_id="O1">
            <title>Final Analysis Population (APV30005)</title>
            <description>FPV +/- RTV + background regimen in participants who remained in APV30005 after 31 January 2006</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Adverse Event (AE): Final Analysis</title>
          <description>An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A list of all adverse events is reported in the &quot;Other (Non-Serious) Adverse Events&quot; section.</description>
          <population>All participants who remained in the study after January 31, 2006.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the Indicated Clinical Chemistry Parameters at Weeks 48, 96, 120, 132, 168, 180, 204, and 216</title>
        <description>Fasting blood samples of participants were collected for the assessment of triglycerides (Tri.), cholesterol (Chol.), high density cholesterol (HDL), low density cholesterol (LDL), and fasting blood glucose (FBG). Change from Baseline at Weeks (W) 48, 96, 120, 132, 168, 180, 204, and 216 was calculated as the value at that particular week minus the value at Baseline (Day 1).</description>
        <time_frame>Baseline (Day 1) and Weeks 48, 96, 120, 132, 168, 180, 204, and 216</time_frame>
        <population>All participants receiving at least one dose of FPV or FPV/RTV in Study APV30005. Only those participants contributing data at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FPV Population (APV30001)</title>
            <description>FPV +/- RTV + background regimen in participants who had received FPV in APV30001 (NCT00008554)</description>
          </group>
          <group group_id="O2">
            <title>NFV Population (APV30001)</title>
            <description>FPV +/- RTV + background regimen in participants who had received NFV in APV30001</description>
          </group>
          <group group_id="O3">
            <title>FPV Population (APV30002)</title>
            <description>FPV +/- RTV + background regimen in participants who had received FPV in APV30002 (NCT00009061)</description>
          </group>
          <group group_id="O4">
            <title>NFV Population (APV30002)</title>
            <description>FPV +/- RTV + background regimen in participants who had received NFV in APV30002</description>
          </group>
          <group group_id="O5">
            <title>FPV/RTV QD Population (APV30003)</title>
            <description>FPV +/- RTV + background regimen in participants who had received FPV/RTV QD in APV30003 (no NCT number)</description>
          </group>
          <group group_id="O6">
            <title>FPV/RTV BID Population (APV30003)</title>
            <description>FPV +/- RTV + background regimen in participants who had received FPV/RTV BID in APV30003</description>
          </group>
          <group group_id="O7">
            <title>PI-Naïve Population (Other Studies)</title>
            <description>FPV +/- RTV + background regimen in participants who were PI-naïve prior to enrollment in the parent study</description>
          </group>
          <group group_id="O8">
            <title>PI-Experienced Population (Other Studies)</title>
            <description>FPV +/- RTV + background regimen in participants who were PI-experienced prior to enrollment in the parent study</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Indicated Clinical Chemistry Parameters at Weeks 48, 96, 120, 132, 168, 180, 204, and 216</title>
          <description>Fasting blood samples of participants were collected for the assessment of triglycerides (Tri.), cholesterol (Chol.), high density cholesterol (HDL), low density cholesterol (LDL), and fasting blood glucose (FBG). Change from Baseline at Weeks (W) 48, 96, 120, 132, 168, 180, 204, and 216 was calculated as the value at that particular week minus the value at Baseline (Day 1).</description>
          <population>All participants receiving at least one dose of FPV or FPV/RTV in Study APV30005. Only those participants contributing data at the indicated time points were analyzed.</population>
          <units>milligrams per deciliter (mg/dl)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="159"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="61"/>
                <count group_id="O6" value="65"/>
                <count group_id="O7" value="77"/>
                <count group_id="O8" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tri.; W 48, n=54, 14, 159, 38, 61, 65, 77, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="-34" upper_limit="42"/>
                    <measurement group_id="O2" value="-41" lower_limit="-63" upper_limit="-20"/>
                    <measurement group_id="O3" value="51" lower_limit="14" upper_limit="118"/>
                    <measurement group_id="O4" value="20" lower_limit="-19" upper_limit="57"/>
                    <measurement group_id="O5" value="9" lower_limit="-25" upper_limit="44"/>
                    <measurement group_id="O6" value="14" lower_limit="-69" upper_limit="66"/>
                    <measurement group_id="O7" value="5" lower_limit="-27" upper_limit="58"/>
                    <measurement group_id="O8" value="-54" lower_limit="-96" upper_limit="-12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tri.; W 96, n=92, 13, 132 36, 47, 52, 67, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="-26" upper_limit="43"/>
                    <measurement group_id="O2" value="-48" lower_limit="-101" upper_limit="8"/>
                    <measurement group_id="O3" value="47" lower_limit="10" upper_limit="101"/>
                    <measurement group_id="O4" value="15" lower_limit="-22" upper_limit="48"/>
                    <measurement group_id="O5" value="16" lower_limit="-51" upper_limit="40"/>
                    <measurement group_id="O6" value="34" lower_limit="-21" upper_limit="118"/>
                    <measurement group_id="O7" value="-5" lower_limit="-35" upper_limit="42"/>
                    <measurement group_id="O8" value="7" lower_limit="-3" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tri.; W 120, n=84, 14, 137, 33, 45, 49, 61, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="-24" upper_limit="59"/>
                    <measurement group_id="O2" value="-33" lower_limit="-77" upper_limit="0"/>
                    <measurement group_id="O3" value="43" lower_limit="2" upper_limit="121"/>
                    <measurement group_id="O4" value="-4" lower_limit="-24" upper_limit="69"/>
                    <measurement group_id="O5" value="13" lower_limit="-27" upper_limit="49"/>
                    <measurement group_id="O6" value="22" lower_limit="-39" upper_limit="96"/>
                    <measurement group_id="O7" value="-4" lower_limit="-50" upper_limit="50"/>
                    <measurement group_id="O8" value="-73" lower_limit="-283" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tri.; W 132, n=82, 12, 128, 32, 40, 44, 61, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="-27" upper_limit="46"/>
                    <measurement group_id="O2" value="-2" lower_limit="-66" upper_limit="6"/>
                    <measurement group_id="O3" value="47" lower_limit="-0" upper_limit="101"/>
                    <measurement group_id="O4" value="18" lower_limit="-21" upper_limit="58"/>
                    <measurement group_id="O5" value="14" lower_limit="-63" upper_limit="65"/>
                    <measurement group_id="O6" value="18" lower_limit="-61" upper_limit="63"/>
                    <measurement group_id="O7" value="6" lower_limit="-48" upper_limit="32"/>
                    <measurement group_id="O8" value="-129" lower_limit="-343" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tri.; W 168, n=71, 14, 123, 31, 31, 40, 20, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="-27" upper_limit="66"/>
                    <measurement group_id="O2" value="-12" lower_limit="-58" upper_limit="25"/>
                    <measurement group_id="O3" value="27" lower_limit="-19" upper_limit="86"/>
                    <measurement group_id="O4" value="4" lower_limit="-16" upper_limit="49"/>
                    <measurement group_id="O5" value="29" lower_limit="-55" upper_limit="59"/>
                    <measurement group_id="O6" value="42" lower_limit="-25" upper_limit="177"/>
                    <measurement group_id="O7" value="5" lower_limit="-32" upper_limit="27"/>
                    <measurement group_id="O8" value="-167" lower_limit="-238" upper_limit="-10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tri.; W 180, n=73, 12, 114, 30, 33, 38, 61, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="-38" upper_limit="43"/>
                    <measurement group_id="O2" value="-41" lower_limit="-89" upper_limit="7"/>
                    <measurement group_id="O3" value="37" lower_limit="4" upper_limit="87"/>
                    <measurement group_id="O4" value="18" lower_limit="-16" upper_limit="81"/>
                    <measurement group_id="O5" value="13" lower_limit="-27" upper_limit="63"/>
                    <measurement group_id="O6" value="8" lower_limit="-95" upper_limit="112"/>
                    <measurement group_id="O7" value="-2" lower_limit="-38" upper_limit="20"/>
                    <measurement group_id="O8" value="-170" lower_limit="-267" upper_limit="-56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tri.; W 204, n=73, 12, 113, 23, 20, 26, 61, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="-26" upper_limit="44"/>
                    <measurement group_id="O2" value="-36" lower_limit="-88" upper_limit="-14"/>
                    <measurement group_id="O3" value="43" lower_limit="8" upper_limit="87"/>
                    <measurement group_id="O4" value="12" lower_limit="-18" upper_limit="54"/>
                    <measurement group_id="O5" value="4" lower_limit="-45" upper_limit="28"/>
                    <measurement group_id="O6" value="49" lower_limit="-26" upper_limit="161"/>
                    <measurement group_id="O7" value="12" lower_limit="-4" upper_limit="33"/>
                    <measurement group_id="O8" value="NA">No participants were analyzed in this arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tri.; W 216, n=76, 0, 111, 2, 5, 11, 61, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="-35" upper_limit="49"/>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this arm at this time point.</measurement>
                    <measurement group_id="O3" value="39" lower_limit="4" upper_limit="97"/>
                    <measurement group_id="O4" value="98" lower_limit="34" upper_limit="163"/>
                    <measurement group_id="O5" value="-7" lower_limit="-165" upper_limit="57"/>
                    <measurement group_id="O6" value="66" lower_limit="-33" upper_limit="160"/>
                    <measurement group_id="O7" value="NA">No participants were analyzed in this arm at this time point.</measurement>
                    <measurement group_id="O8" value="NA">No participants were analyzed in this arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chol.; W 48, n=54, 14, 159, 38, 61, 65, 77, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" lower_limit="23" upper_limit="70"/>
                    <measurement group_id="O2" value="3" lower_limit="-32" upper_limit="13"/>
                    <measurement group_id="O3" value="53" lower_limit="26" upper_limit="77"/>
                    <measurement group_id="O4" value="10" lower_limit="-6" upper_limit="26"/>
                    <measurement group_id="O5" value="14" lower_limit="-9" upper_limit="34"/>
                    <measurement group_id="O6" value="13" lower_limit="-12" upper_limit="33"/>
                    <measurement group_id="O7" value="8" lower_limit="-13" upper_limit="22"/>
                    <measurement group_id="O8" value="22" lower_limit="-14" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chol.; W 96, n=92, 13, 132, 36, 47, 52, 67, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" lower_limit="19" upper_limit="58"/>
                    <measurement group_id="O2" value="-3" lower_limit="-16" upper_limit="25"/>
                    <measurement group_id="O3" value="46" lower_limit="21" upper_limit="68"/>
                    <measurement group_id="O4" value="8" lower_limit="-14" upper_limit="23"/>
                    <measurement group_id="O5" value="12" lower_limit="-15" upper_limit="26"/>
                    <measurement group_id="O6" value="10" lower_limit="-13" upper_limit="38"/>
                    <measurement group_id="O7" value="13" lower_limit="-9" upper_limit="32"/>
                    <measurement group_id="O8" value="19" lower_limit="1" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chol.; W 120, n=84, 14, 137, 33, 45, 49, 61, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" lower_limit="22" upper_limit="64"/>
                    <measurement group_id="O2" value="-9" lower_limit="-17" upper_limit="9"/>
                    <measurement group_id="O3" value="50" lower_limit="23" upper_limit="73"/>
                    <measurement group_id="O4" value="9" lower_limit="-15" upper_limit="23"/>
                    <measurement group_id="O5" value="11" lower_limit="-16" upper_limit="25"/>
                    <measurement group_id="O6" value="22" lower_limit="-8" upper_limit="31"/>
                    <measurement group_id="O7" value="13" lower_limit="-10" upper_limit="30"/>
                    <measurement group_id="O8" value="32" lower_limit="12" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chol.; W 132, n=82, 13, 128, 32, 40, 44, 61, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" lower_limit="22" upper_limit="72"/>
                    <measurement group_id="O2" value="14" lower_limit="-23" upper_limit="32"/>
                    <measurement group_id="O3" value="47" lower_limit="18" upper_limit="82"/>
                    <measurement group_id="O4" value="13" lower_limit="-10" upper_limit="38"/>
                    <measurement group_id="O5" value="14" lower_limit="-13" upper_limit="30"/>
                    <measurement group_id="O6" value="-4" lower_limit="-24" upper_limit="30"/>
                    <measurement group_id="O7" value="2" lower_limit="-12" upper_limit="27"/>
                    <measurement group_id="O8" value="12" lower_limit="-38" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chol.; W 168, n=71, 14, 123, 31, 31, 40, 20, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" lower_limit="28" upper_limit="78"/>
                    <measurement group_id="O2" value="6" lower_limit="-18" upper_limit="38"/>
                    <measurement group_id="O3" value="47" lower_limit="18" upper_limit="76"/>
                    <measurement group_id="O4" value="21" lower_limit="-4" upper_limit="60"/>
                    <measurement group_id="O5" value="18" lower_limit="-15" upper_limit="34"/>
                    <measurement group_id="O6" value="9" lower_limit="-22" upper_limit="31"/>
                    <measurement group_id="O7" value="6" lower_limit="-1" upper_limit="23"/>
                    <measurement group_id="O8" value="28" lower_limit="19" upper_limit="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chol.; W 180, n=73, 12, 114, 30, 33, 38, 61, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" lower_limit="22" upper_limit="73"/>
                    <measurement group_id="O2" value="-4" lower_limit="-16" upper_limit="28"/>
                    <measurement group_id="O3" value="53" lower_limit="24" upper_limit="78"/>
                    <measurement group_id="O4" value="19" lower_limit="-4" upper_limit="40"/>
                    <measurement group_id="O5" value="3" lower_limit="-8" upper_limit="34"/>
                    <measurement group_id="O6" value="9" lower_limit="-19" upper_limit="27"/>
                    <measurement group_id="O7" value="5" lower_limit="-1" upper_limit="17"/>
                    <measurement group_id="O8" value="43" lower_limit="1" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chol.; W 204, n=73, 12, 113, 23, 20, 26, 61, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" lower_limit="18" upper_limit="76"/>
                    <measurement group_id="O2" value="5" lower_limit="-32" upper_limit="22"/>
                    <measurement group_id="O3" value="53" lower_limit="22" upper_limit="80"/>
                    <measurement group_id="O4" value="22" lower_limit="-18" upper_limit="61"/>
                    <measurement group_id="O5" value="-3" lower_limit="-38" upper_limit="18"/>
                    <measurement group_id="O6" value="11" lower_limit="-9" upper_limit="36"/>
                    <measurement group_id="O7" value="-5" lower_limit="-12" upper_limit="14"/>
                    <measurement group_id="O8" value="NA">No participants were analyzed in this arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chol.; W 216, n=76, 0, 111, 2, 5, 11, 61, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" lower_limit="25" upper_limit="79"/>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this arm at this time point.</measurement>
                    <measurement group_id="O3" value="47" lower_limit="24" upper_limit="70"/>
                    <measurement group_id="O4" value="30" lower_limit="24" upper_limit="35"/>
                    <measurement group_id="O5" value="-65" lower_limit="-82" upper_limit="-48"/>
                    <measurement group_id="O6" value="28" lower_limit="-8" upper_limit="34"/>
                    <measurement group_id="O7" value="NA">No participants were analyzed in this arm at this time point.</measurement>
                    <measurement group_id="O8" value="NA">No participants were analyzed in this arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Chol.; W 48, n=54, 14, 159, 38, 61, 65, 77 59,</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="4" upper_limit="18"/>
                    <measurement group_id="O2" value="-0.2" lower_limit="-5" upper_limit="5"/>
                    <measurement group_id="O3" value="8" lower_limit="2" upper_limit="15"/>
                    <measurement group_id="O4" value="3" lower_limit="-5" upper_limit="8"/>
                    <measurement group_id="O5" value="6" lower_limit="-1" upper_limit="10"/>
                    <measurement group_id="O6" value="2" lower_limit="-4" upper_limit="11"/>
                    <measurement group_id="O7" value="3" lower_limit="-3" upper_limit="8"/>
                    <measurement group_id="O8" value="8" lower_limit="5" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Chol.; W 96, n=92, 13, 132, 36, 47, 52, 67, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="4" upper_limit="18"/>
                    <measurement group_id="O2" value="8" lower_limit="1" upper_limit="16"/>
                    <measurement group_id="O3" value="12" lower_limit="4" upper_limit="19"/>
                    <measurement group_id="O4" value="4" lower_limit="-2" upper_limit="10"/>
                    <measurement group_id="O5" value="6" lower_limit="-1" upper_limit="12"/>
                    <measurement group_id="O6" value="2" lower_limit="-6" upper_limit="10"/>
                    <measurement group_id="O7" value="4" lower_limit="-3" upper_limit="8"/>
                    <measurement group_id="O8" value="5" lower_limit="4" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Chol.; W 120, n=84, 14, 137, 33, 45, 49, 61,40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="6" upper_limit="17"/>
                    <measurement group_id="O2" value="5" lower_limit="1" upper_limit="11"/>
                    <measurement group_id="O3" value="12" lower_limit="3" upper_limit="20"/>
                    <measurement group_id="O4" value="7" lower_limit="0" upper_limit="15"/>
                    <measurement group_id="O5" value="8" lower_limit="1" upper_limit="13"/>
                    <measurement group_id="O6" value="4" lower_limit="-2" upper_limit="9"/>
                    <measurement group_id="O7" value="5" lower_limit="-6" upper_limit="11"/>
                    <measurement group_id="O8" value="10" lower_limit="9" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Chol.; W 132, n=82, 13, 128, 32, 40, 44, 61,40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="4" upper_limit="21"/>
                    <measurement group_id="O2" value="6" lower_limit="-1" upper_limit="13"/>
                    <measurement group_id="O3" value="12" lower_limit="7" upper_limit="20"/>
                    <measurement group_id="O4" value="9" lower_limit="3" upper_limit="17"/>
                    <measurement group_id="O5" value="6" lower_limit="3" upper_limit="15"/>
                    <measurement group_id="O6" value="5" lower_limit="-2" upper_limit="12"/>
                    <measurement group_id="O7" value="3" lower_limit="-6" upper_limit="11"/>
                    <measurement group_id="O8" value="16" lower_limit="12" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Chol.; W 168, n=71, 14, 123, 31, 31, 40, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="9" upper_limit="24"/>
                    <measurement group_id="O2" value="13" lower_limit="3" upper_limit="21"/>
                    <measurement group_id="O3" value="17" lower_limit="6" upper_limit="24"/>
                    <measurement group_id="O4" value="12" lower_limit="3" upper_limit="17"/>
                    <measurement group_id="O5" value="8" lower_limit="-1" upper_limit="15"/>
                    <measurement group_id="O6" value="2" lower_limit="-5" upper_limit="8"/>
                    <measurement group_id="O7" value="10" lower_limit="3" upper_limit="14"/>
                    <measurement group_id="O8" value="5" lower_limit="4" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Chol.; W 180, n=73, 12, 114, 30, 33, 38, 61,40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="9" upper_limit="24"/>
                    <measurement group_id="O2" value="4" lower_limit="1" upper_limit="16"/>
                    <measurement group_id="O3" value="15" lower_limit="7" upper_limit="25"/>
                    <measurement group_id="O4" value="10" lower_limit="3" upper_limit="17"/>
                    <measurement group_id="O5" value="7" lower_limit="1" upper_limit="12"/>
                    <measurement group_id="O6" value="4" lower_limit="-4" upper_limit="9"/>
                    <measurement group_id="O7" value="12">Only one participant was analyzed in this arm at this time point.</measurement>
                    <measurement group_id="O8" value="18" lower_limit="15" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Chol.; W 204, n=73, 10, 113, 23, 20, 26, 61,40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="8" upper_limit="26"/>
                    <measurement group_id="O2" value="10" lower_limit="-0.2" upper_limit="16"/>
                    <measurement group_id="O3" value="17" lower_limit="10" upper_limit="26"/>
                    <measurement group_id="O4" value="15" lower_limit="2" upper_limit="22"/>
                    <measurement group_id="O5" value="6" lower_limit="-0.19" upper_limit="15"/>
                    <measurement group_id="O6" value="2" lower_limit="-7" upper_limit="12"/>
                    <measurement group_id="O7" value="3">Only one participant was analyzed in this arm at this time point.</measurement>
                    <measurement group_id="O8" value="NA">No participants were analyzed in this arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Chol.; W 216, n=76, 0, 111, 2, 5, 11, 61, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="9" upper_limit="26"/>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this arm at this time point.</measurement>
                    <measurement group_id="O3" value="17" lower_limit="7" upper_limit="25"/>
                    <measurement group_id="O4" value="4" lower_limit="3" upper_limit="6"/>
                    <measurement group_id="O5" value="3" lower_limit="-5" upper_limit="4"/>
                    <measurement group_id="O6" value="6" lower_limit="-3" upper_limit="12"/>
                    <measurement group_id="O7" value="NA">No participants were analyzed in this arm at this time point.</measurement>
                    <measurement group_id="O8" value="NA">No participants were analyzed in this arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Chol.; W 48, n=50, 13, 145, 35, 53, 50, 67, 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="20" upper_limit="53"/>
                    <measurement group_id="O2" value="10" lower_limit="-11" upper_limit="16"/>
                    <measurement group_id="O3" value="30" lower_limit="10" upper_limit="53"/>
                    <measurement group_id="O4" value="0" lower_limit="-8" upper_limit="19"/>
                    <measurement group_id="O5" value="2" lower_limit="-24" upper_limit="21"/>
                    <measurement group_id="O6" value="-1" lower_limit="-15" upper_limit="24"/>
                    <measurement group_id="O7" value="3" lower_limit="-13" upper_limit="21"/>
                    <measurement group_id="O8" value="17" lower_limit="10" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Chol.; W 96, n=87, 12, 121, 34, 43, 43, 63, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="9" upper_limit="40"/>
                    <measurement group_id="O2" value="-2" lower_limit="-10" upper_limit="12"/>
                    <measurement group_id="O3" value="21" lower_limit="4" upper_limit="45"/>
                    <measurement group_id="O4" value="1" lower_limit="-20" upper_limit="17"/>
                    <measurement group_id="O5" value="3" lower_limit="-20" upper_limit="15"/>
                    <measurement group_id="O6" value="0" lower_limit="-18" upper_limit="27"/>
                    <measurement group_id="O7" value="7" lower_limit="-12" upper_limit="25"/>
                    <measurement group_id="O8" value="15" lower_limit="13" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Chol.; W 120, n=78, 13, 120, 29, 40, 39, 61,40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="10" upper_limit="44"/>
                    <measurement group_id="O2" value="-4" lower_limit="-11" upper_limit="8"/>
                    <measurement group_id="O3" value="21" lower_limit="3" upper_limit="41"/>
                    <measurement group_id="O4" value="-2" lower_limit="-21" upper_limit="11"/>
                    <measurement group_id="O5" value="-6" lower_limit="-20" upper_limit="8"/>
                    <measurement group_id="O6" value="12" lower_limit="-19" upper_limit="25"/>
                    <measurement group_id="O7" value="3" lower_limit="-9" upper_limit="22"/>
                    <measurement group_id="O8" value="38" lower_limit="22" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Chol.; W 132, n=78, 12, 117, 29, 36, 37, 58,34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="10" upper_limit="42"/>
                    <measurement group_id="O2" value="11" lower_limit="-20" upper_limit="18"/>
                    <measurement group_id="O3" value="24" lower_limit="-3" upper_limit="43"/>
                    <measurement group_id="O4" value="4" lower_limit="-25" upper_limit="19"/>
                    <measurement group_id="O5" value="-4" lower_limit="-27" upper_limit="20"/>
                    <measurement group_id="O6" value="-2" lower_limit="-20" upper_limit="17"/>
                    <measurement group_id="O7" value="0" lower_limit="-22" upper_limit="20"/>
                    <measurement group_id="O8" value="14" lower_limit="14" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Chol.; W 168, n=63, 13, 115, 30, 28, 34, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37" lower_limit="13" upper_limit="54"/>
                    <measurement group_id="O2" value="-5" lower_limit="-17" upper_limit="20"/>
                    <measurement group_id="O3" value="18" lower_limit="0.3" upper_limit="43"/>
                    <measurement group_id="O4" value="5" lower_limit="-17" upper_limit="23"/>
                    <measurement group_id="O5" value="-3" lower_limit="-25" upper_limit="11"/>
                    <measurement group_id="O6" value="-6" lower_limit="-27" upper_limit="22"/>
                    <measurement group_id="O7" value="-1" lower_limit="-8" upper_limit="2"/>
                    <measurement group_id="O8" value="48" lower_limit="24" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Chol.; W 180, n=67, 11, 111, 27, 29, 30, 61,40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="13" upper_limit="56"/>
                    <measurement group_id="O2" value="1" lower_limit="-8" upper_limit="18"/>
                    <measurement group_id="O3" value="23" lower_limit="4" upper_limit="49"/>
                    <measurement group_id="O4" value="2" lower_limit="-18" upper_limit="14"/>
                    <measurement group_id="O5" value="-2" lower_limit="-16" upper_limit="17"/>
                    <measurement group_id="O6" value="4" lower_limit="-20" upper_limit="18"/>
                    <measurement group_id="O7" value="-7">Only one participant was analyzed in this arm at this time point.</measurement>
                    <measurement group_id="O8" value="54" lower_limit="48" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Chol.; W 204, n=70, 11, 105, 22, 19, 19, 61,40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="8" upper_limit="51"/>
                    <measurement group_id="O2" value="5" lower_limit="-24" upper_limit="19"/>
                    <measurement group_id="O3" value="22" lower_limit="2" upper_limit="46"/>
                    <measurement group_id="O4" value="13" lower_limit="-18" upper_limit="40"/>
                    <measurement group_id="O5" value="-14" lower_limit="-32" upper_limit="12"/>
                    <measurement group_id="O6" value="1" lower_limit="-26" upper_limit="25"/>
                    <measurement group_id="O7" value="-45">Only one participant was analyzed in this arm at this time point.</measurement>
                    <measurement group_id="O8" value="NA">No participants were analyzed in this arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Chol.; W 216, n=69, 0, 105, 2, 4, 10, 61, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" lower_limit="7" upper_limit="55"/>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this arm at this time point.</measurement>
                    <measurement group_id="O3" value="21" lower_limit="-3" upper_limit="45"/>
                    <measurement group_id="O4" value="5" lower_limit="-15" upper_limit="26"/>
                    <measurement group_id="O5" value="-39" lower_limit="-66" upper_limit="-23"/>
                    <measurement group_id="O6" value="3" lower_limit="-42" upper_limit="45"/>
                    <measurement group_id="O7" value="NA">No participants were analyzed in this arm at this time point.</measurement>
                    <measurement group_id="O8" value="NA">No participants were analyzed in this arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FBG; W 48, n=54, 14, 158, 36, 61, 65, 77, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="0" upper_limit="16"/>
                    <measurement group_id="O2" value="-2" lower_limit="-4" upper_limit="2"/>
                    <measurement group_id="O3" value="3.6" lower_limit="-5" upper_limit="11"/>
                    <measurement group_id="O4" value="-4" lower_limit="-9" upper_limit="6"/>
                    <measurement group_id="O5" value="2" lower_limit="-4" upper_limit="11"/>
                    <measurement group_id="O6" value="7" lower_limit="-2" upper_limit="13"/>
                    <measurement group_id="O7" value="0" lower_limit="-9" upper_limit="11"/>
                    <measurement group_id="O8" value="0" lower_limit="-16" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FBG; W 96, n=92, 13, 132, 34, 47, 52, 67, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="-4" upper_limit="11"/>
                    <measurement group_id="O2" value="0" lower_limit="-5" upper_limit="4"/>
                    <measurement group_id="O3" value="1.8" lower_limit="-4" upper_limit="11"/>
                    <measurement group_id="O4" value="-5" lower_limit="-11" upper_limit="0"/>
                    <measurement group_id="O5" value="0" lower_limit="-9" upper_limit="9"/>
                    <measurement group_id="O6" value="4" lower_limit="-5" upper_limit="14"/>
                    <measurement group_id="O7" value="0" lower_limit="-11" upper_limit="7"/>
                    <measurement group_id="O8" value="-5" lower_limit="-11" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FBG; W 120, n=84, 14, 136, 31, 44, 48, 61, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="-2" upper_limit="14"/>
                    <measurement group_id="O2" value="-2" lower_limit="-7" upper_limit="2"/>
                    <measurement group_id="O3" value="1.8" lower_limit="-5" upper_limit="11"/>
                    <measurement group_id="O4" value="-9" lower_limit="-16" upper_limit="-4"/>
                    <measurement group_id="O5" value="1" lower_limit="-6" upper_limit="7"/>
                    <measurement group_id="O6" value="2" lower_limit="-10" upper_limit="12"/>
                    <measurement group_id="O7" value="0" lower_limit="-7" upper_limit="11"/>
                    <measurement group_id="O8" value="-2" lower_limit="-11" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FBG; W 132, n=82, 13, 128, 30, 40, 44, 61, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-5" upper_limit="13"/>
                    <measurement group_id="O2" value="0" lower_limit="-5" upper_limit="2"/>
                    <measurement group_id="O3" value="0" lower_limit="-7" upper_limit="11"/>
                    <measurement group_id="O4" value="-4" lower_limit="-5" upper_limit="4"/>
                    <measurement group_id="O5" value="0" lower_limit="-9" upper_limit="5"/>
                    <measurement group_id="O6" value="0" lower_limit="-10" upper_limit="7"/>
                    <measurement group_id="O7" value="7" lower_limit="-2" upper_limit="16"/>
                    <measurement group_id="O8" value="-14" lower_limit="-21" upper_limit="-8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FBG; W 168, n=71, 14, 123, 29, 31, 40, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="-5" upper_limit="11"/>
                    <measurement group_id="O2" value="1" lower_limit="-4" upper_limit="4"/>
                    <measurement group_id="O3" value="0" lower_limit="-9" upper_limit="9"/>
                    <measurement group_id="O4" value="-2" lower_limit="-7" upper_limit="5"/>
                    <measurement group_id="O5" value="2" lower_limit="-4" upper_limit="7"/>
                    <measurement group_id="O6" value="-3" lower_limit="-14" upper_limit="9"/>
                    <measurement group_id="O7" value="21" lower_limit="13" upper_limit="24"/>
                    <measurement group_id="O8" value="0" lower_limit="-2" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FBG; W 180, n=73, 12, 112, 28, 33, 37, 61, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="-7" upper_limit="11"/>
                    <measurement group_id="O2" value="-0.9" lower_limit="-4" upper_limit="1"/>
                    <measurement group_id="O3" value="2.7" lower_limit="-5" upper_limit="9.0"/>
                    <measurement group_id="O4" value="-1.8" lower_limit="-7" upper_limit="7"/>
                    <measurement group_id="O5" value="2" lower_limit="-4" upper_limit="11"/>
                    <measurement group_id="O6" value="2" lower_limit="-6" upper_limit="7"/>
                    <measurement group_id="O7" value="20" lower_limit="14" upper_limit="29"/>
                    <measurement group_id="O8" value="-1" lower_limit="-5" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FBG; W 204, n=73, 12, 115, 23, 20, 26, 61, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="-5" upper_limit="9"/>
                    <measurement group_id="O2" value="4" lower_limit="-8" upper_limit="9"/>
                    <measurement group_id="O3" value="1.8" lower_limit="-5" upper_limit="11"/>
                    <measurement group_id="O4" value="0" lower_limit="-5" upper_limit="5"/>
                    <measurement group_id="O5" value="0" lower_limit="-7" upper_limit="7"/>
                    <measurement group_id="O6" value="5" lower_limit="-5" upper_limit="16"/>
                    <measurement group_id="O7" value="21" lower_limit="14" upper_limit="25"/>
                    <measurement group_id="O8" value="NA">No participants were analyzed in this arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FBG; W 216, n=75, 0, 110, 2, 5, 11, 61, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-5" upper_limit="7"/>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this arm at this time point.</measurement>
                    <measurement group_id="O3" value="5.4" lower_limit="-2" upper_limit="13"/>
                    <measurement group_id="O4" value="2" lower_limit="-2" upper_limit="5"/>
                    <measurement group_id="O5" value="0" lower_limit="-7" upper_limit="16"/>
                    <measurement group_id="O6" value="11" lower_limit="-2" upper_limit="20"/>
                    <measurement group_id="O7" value="NA">No participants were analyzed in this arm at this time point.</measurement>
                    <measurement group_id="O8" value="NA">No participants were analyzed in this arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Values of the Indicated Clinical Chemistry Parameters at Weeks 120, 180, 204, 216, and 432</title>
        <description>Fasting blood samples of participants were collected for the assessment of triglycerides, cholesterol, high density cholesterol (HDL), low density cholesterol (LDL), and fasting blood glucose (FBG).</description>
        <time_frame>Weeks 120, 180, 204, 216, and 432</time_frame>
        <population>All participants who remained in the study after January 31, 2006. Only those participants contributing data at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Final Analysis Population (APV30005)</title>
            <description>FPV +/- RTV + background regimen in participants who remained in APV30005 after 31 January 2006</description>
          </group>
        </group_list>
        <measure>
          <title>Median Values of the Indicated Clinical Chemistry Parameters at Weeks 120, 180, 204, 216, and 432</title>
          <description>Fasting blood samples of participants were collected for the assessment of triglycerides, cholesterol, high density cholesterol (HDL), low density cholesterol (LDL), and fasting blood glucose (FBG).</description>
          <population>All participants who remained in the study after January 31, 2006. Only those participants contributing data at the indicated time points were analyzed.</population>
          <units>milligrams per deciliter (mg/dl)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Triglycerides; Week 120, n=14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="237" lower_limit="187" upper_limit="372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides; Week 180, n=14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="248" lower_limit="193" upper_limit="312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides; Week 204, n=106</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137" lower_limit="95" upper_limit="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides; Week 216, n=102</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120" lower_limit="92" upper_limit="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides; Week 432, n=40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132" lower_limit="76" upper_limit="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol; Week 120, n=14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202" lower_limit="183" upper_limit="284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol; Week 180, n=14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206" lower_limit="20" upper_limit="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol; Week 204, n=106</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="201" lower_limit="166" upper_limit="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol; Week 216, n=102</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205" lower_limit="169" upper_limit="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol; Week 432, n=40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192" lower_limit="168" upper_limit="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Cholesterol; Week 120, n=14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="34" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Cholesterol; Week 180, n=14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="34" upper_limit="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Cholesterol; Week 204, n=106</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" lower_limit="42" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Cholesterol; Week 216, n=102</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" lower_limit="44" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Cholesterol; Week 432, n=40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" lower_limit="44" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Cholesterol; Week 120, n=14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="34" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Cholesterol; Week 180, n=14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="34" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Cholesterol; Week 204, n=106</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" lower_limit="42" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Cholesterol; Week 216, n=102</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" lower_limit="44" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Cholesterol; Week 432, n=40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" lower_limit="44" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FBG; Week 120, n=14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="79" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FBG; Week 180, n=14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="85" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FBG; Week 204, n=106</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="81" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FBG; Week 216, n=104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="81" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FBG Cholesterol; Week 432, n=40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="83" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the Total Cholesterol/HDL Ratio at Weeks 48, 120, 180, 204, and 216</title>
        <description>blood samples of participants were collected for the assessment of the total cholesterol/HDL ratio. The ratio of total cholesterol/HDL was calculated by dividing the value of total cholesterol by the value of HDL. Change from Baseline at Weeks 48, 120, 180, 204, and 216 was calculated as the value at that particular week minus the value at Baseline (Day 1).</description>
        <time_frame>Baseline (Day 1) and Weeks 48, 120, 180, 204, and 216</time_frame>
        <population>All participants receiving FPV or FPV/RTV in Study APV30005 having previously participated in Study APV30001 or Study APV30002. Only those participants contributing data at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FPV Population (APV30001)</title>
            <description>FPV +/- RTV + background regimen in participants who had received FPV in APV30001 (NCT00008554)</description>
          </group>
          <group group_id="O2">
            <title>NFV Population (APV30001)</title>
            <description>FPV +/- RTV + background regimen in participants who had received NFV in APV30001</description>
          </group>
          <group group_id="O3">
            <title>FPV Population (APV30002)</title>
            <description>FPV +/- RTV + background regimen in participants who had received FPV in APV30002 (NCT00009061)</description>
          </group>
          <group group_id="O4">
            <title>NFV Population (APV30002)</title>
            <description>FPV +/- RTV + background regimen in participants who had received NFV in APV30002</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Total Cholesterol/HDL Ratio at Weeks 48, 120, 180, 204, and 216</title>
          <description>blood samples of participants were collected for the assessment of the total cholesterol/HDL ratio. The ratio of total cholesterol/HDL was calculated by dividing the value of total cholesterol by the value of HDL. Change from Baseline at Weeks 48, 120, 180, 204, and 216 was calculated as the value at that particular week minus the value at Baseline (Day 1).</description>
          <population>All participants receiving FPV or FPV/RTV in Study APV30005 having previously participated in Study APV30001 or Study APV30002. Only those participants contributing data at the indicated time points were analyzed.</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="159"/>
                <count group_id="O4" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48, n=54, 14, 159, 38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-0.4" upper_limit="0.8"/>
                    <measurement group_id="O2" value="-0.4" lower_limit="-1.0" upper_limit="0.6"/>
                    <measurement group_id="O3" value="0.4" lower_limit="-0.3" upper_limit="1.2"/>
                    <measurement group_id="O4" value="0.1" lower_limit="-0.3" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120, n=84, 14, 137, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" lower_limit="-0.7" upper_limit="0.4"/>
                    <measurement group_id="O2" value="-0.6" lower_limit="-1.1" upper_limit="-0.2"/>
                    <measurement group_id="O3" value="-0.1" lower_limit="-0.8" upper_limit="0.7"/>
                    <measurement group_id="O4" value="-0.2" lower_limit="-0.7" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 180, n=73, 12, 114, 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" lower_limit="-1.1" upper_limit="0.2"/>
                    <measurement group_id="O2" value="-0.6" lower_limit="-1.6" upper_limit="0.1"/>
                    <measurement group_id="O3" value="-0.3" lower_limit="-1.0" upper_limit="0.4"/>
                    <measurement group_id="O4" value="-0.3" lower_limit="-1.3" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 204, n=73, 12, 113, 23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" lower_limit="-1.0" upper_limit="0.1"/>
                    <measurement group_id="O2" value="-0.6" lower_limit="-1.7" upper_limit="0.1"/>
                    <measurement group_id="O3" value="-0.4" lower_limit="-1.0" upper_limit="0.1"/>
                    <measurement group_id="O4" value="-0.4" lower_limit="-0.9" upper_limit="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 216, n=76, 0, 111, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" lower_limit="-1.0" upper_limit="0.2"/>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this arm at this time point.</measurement>
                    <measurement group_id="O3" value="-0.5" lower_limit="-1.1" upper_limit="0.1"/>
                    <measurement group_id="O4" value="0.3" lower_limit="0.1" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the Total Cholesterol/HDL Ratio at Weeks 48, 96, 132, and 168</title>
        <description>Fasting blood samples of participants were collected for the assessment of the total cholesterol/HDL ratio. The ratio of total cholesterol/HDL was calculated by dividing the value of total cholesterol by the value of HDL. Change from Baseline at Weeks 48, 96, 132, and 168 was calculated as the value at that particular week minus the value at Baseline (Day 1).</description>
        <time_frame>Baseline (Day 1) and Weeks 48, 96, 132, and 168</time_frame>
        <population>All participants receiving FPV or FPV/RTV in Study APV30005 having previously participated in Study APV30003 or other studies. Only those participants contributing data at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FPV/RTV QD Population (APV30003)</title>
            <description>FPV +/- RTV + background regimen in participants who had received FPV/RTV QD in APV30003 (no NCT number)</description>
          </group>
          <group group_id="O2">
            <title>FPV/RTV BID Population (APV30003)</title>
            <description>FPV +/- RTV + background regimen in participants who had received FPV/RTV BID in APV30003</description>
          </group>
          <group group_id="O3">
            <title>PI-Naïve Population (Other Studies)</title>
            <description>FPV +/- RTV + background regimen in participants who were PI-naïve prior to enrollment in the parent study</description>
          </group>
          <group group_id="O4">
            <title>PI-Experienced Population (Other Studies)</title>
            <description>FPV +/- RTV + background regimen in participants who were PI-experienced prior to enrollment in the parent study</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Total Cholesterol/HDL Ratio at Weeks 48, 96, 132, and 168</title>
          <description>Fasting blood samples of participants were collected for the assessment of the total cholesterol/HDL ratio. The ratio of total cholesterol/HDL was calculated by dividing the value of total cholesterol by the value of HDL. Change from Baseline at Weeks 48, 96, 132, and 168 was calculated as the value at that particular week minus the value at Baseline (Day 1).</description>
          <population>All participants receiving FPV or FPV/RTV in Study APV30005 having previously participated in Study APV30003 or other studies. Only those participants contributing data at the indicated time points were analyzed.</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48, n=61, 65 , 45, 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" lower_limit="-1.1" upper_limit="0.4"/>
                    <measurement group_id="O2" value="-0.3" lower_limit="-1.1" upper_limit="0.8"/>
                    <measurement group_id="O3" value="-0.1" lower_limit="-0.8" upper_limit="0.8"/>
                    <measurement group_id="O4" value="-0.8" lower_limit="-0.8" upper_limit="-0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96, n=47, 52, 42, 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" lower_limit="-1.4" upper_limit="0"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-0.8" upper_limit="0.8"/>
                    <measurement group_id="O3" value="-0.1" lower_limit="-0.7" upper_limit="0.4"/>
                    <measurement group_id="O4" value="-0.3" lower_limit="-0.5" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 132, n=40, 44, 41, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" lower_limit="-1.5" upper_limit="-0.1"/>
                    <measurement group_id="O2" value="-0.6" lower_limit="-1.6" upper_limit="0.5"/>
                    <measurement group_id="O3" value="-0.2" lower_limit="-1.1" upper_limit="1.0"/>
                    <measurement group_id="O4" value="-1.5" lower_limit="-2.7" upper_limit="-0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168, n=31, 40, 3, 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" lower_limit="-1.4" upper_limit="0.3"/>
                    <measurement group_id="O2" value="0.2" lower_limit="-1.0" upper_limit="0.5"/>
                    <measurement group_id="O3" value="-0.6" lower_limit="-1.0" upper_limit="-0.4"/>
                    <measurement group_id="O4" value="-1.4" lower_limit="-1.4" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Value of the Total Cholesterol/HDL Ratio at Weeks 120, 180, 204, 216, and 432</title>
        <description>Fasting blood samples of participants were collected for the assessment of the total cholesterol/HDL ratio. The ratio of total cholesterol/HDL was calculated by dividing the value of total cholesterol by the value of HDL.</description>
        <time_frame>Weeks 120, 180, 204, 216, and 432</time_frame>
        <population>All participants who remained in the study after January 31, 2006. Only those participants contributing data at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Final Analysis Population (APV30005)</title>
            <description>FPV +/- RTV + background regimen in participants who remained in APV30005 after 31 January 2006</description>
          </group>
        </group_list>
        <measure>
          <title>Median Value of the Total Cholesterol/HDL Ratio at Weeks 120, 180, 204, 216, and 432</title>
          <description>Fasting blood samples of participants were collected for the assessment of the total cholesterol/HDL ratio. The ratio of total cholesterol/HDL was calculated by dividing the value of total cholesterol by the value of HDL.</description>
          <population>All participants who remained in the study after January 31, 2006. Only those participants contributing data at the indicated time points were analyzed.</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 120, n=14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="4.5" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 180, n=14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="4.7" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 204, n=106</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="3.0" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 216, n=102</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="3.0" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 432, n=40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="3.3" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Aspartate Aminotransferase (AST), Alanine Transaminase (ALT), and Serum Lipase at Weeks 48, 120, 180, 204, and 216</title>
        <description>Blood samples of participants were collected for the assessment of AST, ALT, and serum lipase. Change from Baseline at Weeks 48, 120, 180, 204, and 216 was calculated as the value at that particular week minus the value at Baseline (Day 1).</description>
        <time_frame>Baseline (Day 1) and Weeks 48, 120, 180, 204, and 216</time_frame>
        <population>All participants receiving FPV or FPV/RTV in Study APV30005 having previously participated in Study APV30001 or Study APV30002. Only those participants contributing data at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FPV Population (APV30001)</title>
            <description>FPV +/- RTV + background regimen in participants who had received FPV in APV30001 (NCT00008554)</description>
          </group>
          <group group_id="O2">
            <title>NFV Population (APV30001)</title>
            <description>FPV +/- RTV + background regimen in participants who had received NFV in APV30001</description>
          </group>
          <group group_id="O3">
            <title>FPV Population (APV30002)</title>
            <description>FPV +/- RTV + background regimen in participants who had received FPV in APV30002 (NCT00009061)</description>
          </group>
          <group group_id="O4">
            <title>NFV Population (APV30002)</title>
            <description>FPV +/- RTV + background regimen in participants who had received NFV in APV30002</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Aspartate Aminotransferase (AST), Alanine Transaminase (ALT), and Serum Lipase at Weeks 48, 120, 180, 204, and 216</title>
          <description>Blood samples of participants were collected for the assessment of AST, ALT, and serum lipase. Change from Baseline at Weeks 48, 120, 180, 204, and 216 was calculated as the value at that particular week minus the value at Baseline (Day 1).</description>
          <population>All participants receiving FPV or FPV/RTV in Study APV30005 having previously participated in Study APV30001 or Study APV30002. Only those participants contributing data at the indicated time points were analyzed.</population>
          <units>units per liter (U/L)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="217"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AST; Week 48, n=117, 17, 215, 47</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7" lower_limit="-14" upper_limit="-1"/>
                    <measurement group_id="O2" value="-2" lower_limit="-3" upper_limit="5"/>
                    <measurement group_id="O3" value="-7" lower_limit="-17" upper_limit="-1"/>
                    <measurement group_id="O4" value="0" lower_limit="-5" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Week 120, n=96, 15, 182, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8" lower_limit="-19" upper_limit="-1"/>
                    <measurement group_id="O2" value="0" lower_limit="-8" upper_limit="4"/>
                    <measurement group_id="O3" value="-8" lower_limit="-19" upper_limit="-2"/>
                    <measurement group_id="O4" value="1" lower_limit="-3" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Week 180, n=80, 12, 154, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10" lower_limit="-19" upper_limit="-3"/>
                    <measurement group_id="O2" value="2" lower_limit="-5" upper_limit="4"/>
                    <measurement group_id="O3" value="-7" lower_limit="-18" upper_limit="-1"/>
                    <measurement group_id="O4" value="-2" lower_limit="-4" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Week 204, n=77, 12, 151, 27</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7" lower_limit="-18" upper_limit="-1"/>
                    <measurement group_id="O2" value="3" lower_limit="-4" upper_limit="6"/>
                    <measurement group_id="O3" value="-7" lower_limit="-18" upper_limit="-1"/>
                    <measurement group_id="O4" value="-2" lower_limit="-4" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Week 216, n=79, 0, 142, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9" lower_limit="-16" upper_limit="-1"/>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this arm at this time point.</measurement>
                    <measurement group_id="O3" value="-7" lower_limit="-17" upper_limit="0"/>
                    <measurement group_id="O4" value="1" lower_limit="-7" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Week 48, n=117, 17, 216, 47</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5" lower_limit="-21" upper_limit="2"/>
                    <measurement group_id="O2" value="0" lower_limit="-3" upper_limit="4"/>
                    <measurement group_id="O3" value="-8" lower_limit="-19" upper_limit="1"/>
                    <measurement group_id="O4" value="2" lower_limit="-2" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Week 120, n=96, 15, 182, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9" lower_limit="-29" upper_limit="2"/>
                    <measurement group_id="O2" value="-1" lower_limit="-6" upper_limit="7"/>
                    <measurement group_id="O3" value="-8" lower_limit="-20" upper_limit="0"/>
                    <measurement group_id="O4" value="4" lower_limit="-6" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Week 180, n=81, 12, 155, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10" lower_limit="-27" upper_limit="-1"/>
                    <measurement group_id="O2" value="3" lower_limit="-3" upper_limit="5"/>
                    <measurement group_id="O3" value="-6" lower_limit="-19" upper_limit="5"/>
                    <measurement group_id="O4" value="1" lower_limit="-5" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Week 204, n=77, 12, 152, 27</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10" lower_limit="-26" upper_limit="0"/>
                    <measurement group_id="O2" value="2" lower_limit="-1" upper_limit="9"/>
                    <measurement group_id="O3" value="-5" lower_limit="-19" upper_limit="4"/>
                    <measurement group_id="O4" value="-1" lower_limit="-7" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Week 216, n=79, 0, 142, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10" lower_limit="-27" upper_limit="2"/>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this arm at this time point.</measurement>
                    <measurement group_id="O3" value="-6" lower_limit="-18" upper_limit="2"/>
                    <measurement group_id="O4" value="-3" lower_limit="-11" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum lipase; Week 48, n=118, 17, 217, 47</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="-2" upper_limit="10"/>
                    <measurement group_id="O2" value="1" lower_limit="-8" upper_limit="5"/>
                    <measurement group_id="O3" value="0" lower_limit="-7" upper_limit="7"/>
                    <measurement group_id="O4" value="-2" lower_limit="-6" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum lipase; Week 120, n=95, 15, 184, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="-4" upper_limit="9"/>
                    <measurement group_id="O2" value="4" lower_limit="-1" upper_limit="6"/>
                    <measurement group_id="O3" value="-1" lower_limit="-6" upper_limit="6"/>
                    <measurement group_id="O4" value="2" lower_limit="-4" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum lipase; Week 180, n=81, 12, 156, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="-3" upper_limit="9"/>
                    <measurement group_id="O2" value="-0.5" lower_limit="-6" upper_limit="4"/>
                    <measurement group_id="O3" value="1" lower_limit="-5" upper_limit="6"/>
                    <measurement group_id="O4" value="1" lower_limit="-5" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum lipase;Week 204, n=78, 12, 153, 27</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="-4" upper_limit="10"/>
                    <measurement group_id="O2" value="0" lower_limit="-5" upper_limit="3"/>
                    <measurement group_id="O3" value="1" lower_limit="-5" upper_limit="7"/>
                    <measurement group_id="O4" value="2" lower_limit="-4" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum lipase; Week 216, n=80, 0, 143, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="-2" upper_limit="11"/>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this arm at this time point.</measurement>
                    <measurement group_id="O3" value="0" lower_limit="-6" upper_limit="9"/>
                    <measurement group_id="O4" value="-3" lower_limit="-27" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Aspartate Aminotransferase (AST), Alanine Transaminase (ALT), and Serum Lipase at Weeks 48, 96, 132, and 168</title>
        <description>Blood samples of participants were collected for the assessment of AST, ALT, and serum lipase. Change from Baseline at Weeks 48, 96, 132, and 168 was calculated as the value at that particular week minus the value at Baseline (Day 1).</description>
        <time_frame>Baseline (Day 1) and Weeks 48, 96, 132, and 168</time_frame>
        <population>All participants receiving FPV or FPV/RTV in Study APV30005 having previously participated in Study APV30003 or other studies. Only those participants contributing data at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>FPV/RTV QD Population (APV30003)</title>
            <description>FPV +/- RTV + background regimen in participants who had received FPV/RTV QD in APV30003 (no NCT number)</description>
          </group>
          <group group_id="O2">
            <title>FPV/RTV BID Population (APV30003)</title>
            <description>FPV +/- RTV + background regimen in participants who had received FPV/RTV BID in APV30003</description>
          </group>
          <group group_id="O3">
            <title>PI-Naïve Population (Other Studies)</title>
            <description>FPV +/- RTV + background regimen in participants who were PI-naïve prior to enrollment in the parent study</description>
          </group>
          <group group_id="O4">
            <title>PI-Experienced Population (Other Studies)</title>
            <description>FPV +/- RTV + background regimen in participants who were PI-experienced prior to enrollment in the parent study</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Aspartate Aminotransferase (AST), Alanine Transaminase (ALT), and Serum Lipase at Weeks 48, 96, 132, and 168</title>
          <description>Blood samples of participants were collected for the assessment of AST, ALT, and serum lipase. Change from Baseline at Weeks 48, 96, 132, and 168 was calculated as the value at that particular week minus the value at Baseline (Day 1).</description>
          <population>All participants receiving FPV or FPV/RTV in Study APV30005 having previously participated in Study APV30003 or other studies. Only those participants contributing data at the indicated time points were analyzed.</population>
          <units>units per liter (U/L)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AST; Week 48, n=73, 78, 83, 65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6" lower_limit="-14" upper_limit="3"/>
                    <measurement group_id="O2" value="-5" lower_limit="-15" upper_limit="-1"/>
                    <measurement group_id="O3" value="1" lower_limit="-3" upper_limit="4"/>
                    <measurement group_id="O4" value="0" lower_limit="-6" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Week 96, n=57, 63, 73, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6" lower_limit="-12" upper_limit="6"/>
                    <measurement group_id="O2" value="-4" lower_limit="-18" upper_limit="2"/>
                    <measurement group_id="O3" value="1" lower_limit="-3" upper_limit="3"/>
                    <measurement group_id="O4" value="-1" lower_limit="-9" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Week 132, n=50, 57, 64, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6" lower_limit="-13" upper_limit="-1"/>
                    <measurement group_id="O2" value="-4" lower_limit="-14" upper_limit="2"/>
                    <measurement group_id="O3" value="2" lower_limit="-3" upper_limit="5"/>
                    <measurement group_id="O4" value="1" lower_limit="-5" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Week 168, n=45, 48, 20, 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6" lower_limit="-14" upper_limit="1"/>
                    <measurement group_id="O2" value="-6" lower_limit="-17" upper_limit="-1"/>
                    <measurement group_id="O3" value="2" lower_limit="-1" upper_limit="5"/>
                    <measurement group_id="O4" value="-1" lower_limit="-10" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Week 48, n=70, 78, 83, 65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" lower_limit="-13" upper_limit="4"/>
                    <measurement group_id="O2" value="-6" lower_limit="-21" upper_limit="1"/>
                    <measurement group_id="O3" value="2" lower_limit="-2" upper_limit="8"/>
                    <measurement group_id="O4" value="0" lower_limit="-9" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Week 96, n=59, 63, 73, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4" lower_limit="-13" upper_limit="9"/>
                    <measurement group_id="O2" value="-3" lower_limit="-21" upper_limit="3"/>
                    <measurement group_id="O3" value="2" lower_limit="-3" upper_limit="6"/>
                    <measurement group_id="O4" value="1" lower_limit="-10" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Week 132, n=51, 58, 64, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" lower_limit="-17" upper_limit="8"/>
                    <measurement group_id="O2" value="-4" lower_limit="-18" upper_limit="3"/>
                    <measurement group_id="O3" value="2" lower_limit="-2" upper_limit="8"/>
                    <measurement group_id="O4" value="2" lower_limit="-10" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Week 168, n=45, 48, 20, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5" lower_limit="-23" upper_limit="4"/>
                    <measurement group_id="O2" value="-5" lower_limit="-22" upper_limit="4"/>
                    <measurement group_id="O3" value="6" lower_limit="-1" upper_limit="9"/>
                    <measurement group_id="O4" value="-3" lower_limit="-16" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum lipase; Week 48, n=72, 78, 57, 64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="-5" upper_limit="8"/>
                    <measurement group_id="O2" value="2" lower_limit="-4" upper_limit="9"/>
                    <measurement group_id="O3" value="1" lower_limit="-3" upper_limit="7"/>
                    <measurement group_id="O4" value="1" lower_limit="-4" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum lipase; Week 96, n=59, 63, 52, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="-4" upper_limit="10"/>
                    <measurement group_id="O2" value="4" lower_limit="-5" upper_limit="12"/>
                    <measurement group_id="O3" value="0" lower_limit="-3" upper_limit="3"/>
                    <measurement group_id="O4" value="3" lower_limit="-4" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum lipase; Week 132, n=52, 58, 47, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="-4" upper_limit="10"/>
                    <measurement group_id="O2" value="4" lower_limit="-1" upper_limit="13"/>
                    <measurement group_id="O3" value="1" lower_limit="-3" upper_limit="5"/>
                    <measurement group_id="O4" value="2" lower_limit="-4" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum lipase; Week 168, n=45, 48, 7, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-8" upper_limit="6"/>
                    <measurement group_id="O2" value="2" lower_limit="-1" upper_limit="11"/>
                    <measurement group_id="O3" value="-5" lower_limit="-14" upper_limit="8"/>
                    <measurement group_id="O4" value="3" lower_limit="-6" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Aspartate Aminotransferase (AST), Alanine Transaminase (ALT), and Serum Lipase Values at Weeks 120, 180, 204, 216, and 432</title>
        <description>Blood samples of participants were collected for the assessment of AST, ALT, and serum lipase.</description>
        <time_frame>Weeks 120, 180, 204, 216, and 432</time_frame>
        <population>All participants who remained in the study after January 31, 2006. Only those participants contributing data at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Final Analysis Population (APV30005)</title>
            <description>FPV +/- RTV + background regimen in participants who remained in APV30005 after 31 January 2006</description>
          </group>
        </group_list>
        <measure>
          <title>Median Aspartate Aminotransferase (AST), Alanine Transaminase (ALT), and Serum Lipase Values at Weeks 120, 180, 204, 216, and 432</title>
          <description>Blood samples of participants were collected for the assessment of AST, ALT, and serum lipase.</description>
          <population>All participants who remained in the study after January 31, 2006. Only those participants contributing data at the indicated time points were analyzed.</population>
          <units>units per liter (U/L)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AST; Week 120, n=14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="17" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Week 180, n=14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="19" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Week 204, n=107</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="16" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Week 216, n=106</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="18" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Week 432, n=41</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="17" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Week 120, n=14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="14" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Week 180, n=14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="22" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Week 204, n=107</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="13" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Week 216, n=106</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="14" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Week 432, n=41</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="15" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum lipase;Week 120, n=14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" lower_limit="31" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum lipase; Week 180, n=14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" lower_limit="29" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum lipase; Week 204, n=107</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" lower_limit="27" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum lipase; Week 216, n=106</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="26" upper_limit="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum lipase; Week 432, n=41</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="30" upper_limit="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) &lt;400 and &lt;50 Copies Per Milliliter at Baseline and Weeks 48, 120, 180, and 216 (MD=F and Observed)</title>
        <description>Blood samples of participants were collected for the assessment of HIV-1RNA copies in plasma. Viral load, measured in RNA copies per milliliter of plasma, is an efficacy measure for antiretroviral drugs. In the MD=F analysis, participants who had missing data at or had discontinued the study prior to a certain time point are classified as non-responders. In the observed analysis (OA), data are presented for the number of participants still enrolled in the study at a certain time point. Participants in the NFV populations had received antiretroviral therapy prior to Baseline.</description>
        <time_frame>Baseline and Weeks 48, 120, 180, and 216</time_frame>
        <population>All participants receiving FPV or FPV/RTV in Study APV30005 having previously participated in Study APV30001 or Study APV30002. No participants were analyzed in the NPV APV30001 arm due to their small number.</population>
        <group_list>
          <group group_id="O1">
            <title>FPV Population (APV30001)</title>
            <description>FPV +/- RTV + background regimen in participants who had received FPV in APV30001 (NCT00008554)</description>
          </group>
          <group group_id="O2">
            <title>NFV Population (APV30001)</title>
            <description>FPV +/- RTV + background regimen in participants who had received NFV in APV30001</description>
          </group>
          <group group_id="O3">
            <title>FPV Population (APV30002)</title>
            <description>FPV +/- RTV + background regimen in participants who had received FPV in APV30002 (NCT00009061)</description>
          </group>
          <group group_id="O4">
            <title>NFV Population (APV30002)</title>
            <description>FPV +/- RTV + background regimen in participants who had received NFV in APV30002</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) &lt;400 and &lt;50 Copies Per Milliliter at Baseline and Weeks 48, 120, 180, and 216 (MD=F and Observed)</title>
          <description>Blood samples of participants were collected for the assessment of HIV-1RNA copies in plasma. Viral load, measured in RNA copies per milliliter of plasma, is an efficacy measure for antiretroviral drugs. In the MD=F analysis, participants who had missing data at or had discontinued the study prior to a certain time point are classified as non-responders. In the observed analysis (OA), data are presented for the number of participants still enrolled in the study at a certain time point. Participants in the NFV populations had received antiretroviral therapy prior to Baseline.</description>
          <population>All participants receiving FPV or FPV/RTV in Study APV30005 having previously participated in Study APV30001 or Study APV30002. No participants were analyzed in the NPV APV30001 arm due to their small number.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="221"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline &lt;400 copies, n=119, 219, 54; MD=F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 &lt;400 copies, n=119, 219, 54; MD=F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O3" value="94"/>
                    <measurement group_id="O4" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120 &lt;400 copies, n=119, 219, 54; MD=F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O3" value="77"/>
                    <measurement group_id="O4" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 180 &lt;400 copies, n=119, 219, 54; MD=F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O3" value="68"/>
                    <measurement group_id="O4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 216 &lt;400 copies, n=119, 219, 0; MD=F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="NA">No participants were analyzed in this arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline &lt;400 copies, n=119, 219, 54; observed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 &lt;400 copies, n=118, 216, 49; observed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O3" value="95"/>
                    <measurement group_id="O4" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120 &lt;400 copies, n=96, 181, 40; observed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O3" value="93"/>
                    <measurement group_id="O4" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 180 &lt;400 copies, n=82, 158, 34; observed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O3" value="94"/>
                    <measurement group_id="O4" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 216 &lt;400 copies, n=80, 142, 0; observed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O3" value="94"/>
                    <measurement group_id="O4" value="NA">No participants were analyzed in this arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline &lt;50 copies, n=119, 219, 54; MD=F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 &lt;50 copies, n=119, 219, 54; MD=F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O3" value="76"/>
                    <measurement group_id="O4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120 &lt;50 copies, n=119, 219, 54; MD=F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O3" value="66"/>
                    <measurement group_id="O4" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 180 &lt;50 copies, n=119, 219, 54; MD=F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O3" value="63"/>
                    <measurement group_id="O4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 216 &lt;50 copies, n=119, 219, 0; MD=F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O3" value="58"/>
                    <measurement group_id="O4" value="NA">No participants were analyzed in this arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline &lt;50 copies, n=119, 219, 54; observed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 &lt;50 copies, n=118, 216, 49; observed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O3" value="77"/>
                    <measurement group_id="O4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120 &lt;50 copies, n=96, 181, 40; observed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O3" value="80"/>
                    <measurement group_id="O4" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 180 &lt;50 copies, n=82, 158, 34; observed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O3" value="88"/>
                    <measurement group_id="O4" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 216 &lt;50 copies, n=80, 142, 0; observed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O3" value="89"/>
                    <measurement group_id="O4" value="NA">No participants were analyzed in this arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Plasma HIV-1RNA &lt;400 and &lt;50 Copies Per Milliliter at Baseline and Weeks 12, 24, 48, 60, 96, and 132 (MD=F and Observed)</title>
        <description>Blood samples of participants were collected for the assessment of HIV-1RNA copies in plasma. Viral load, measured in RNA copies per milliliter of plasma, is an efficacy measure for antiretroviral drugs. In the MD=F analysis, participants who had missing data at or had discontinued the study prior to a certain time point are classified as non-responders. In the observed analysis (OA), data are presented for the number of participants still enrolled in the study at a certain time point.</description>
        <time_frame>Baseline and Weeks 12, 24, 48, 60, 96, and 132</time_frame>
        <population>All participants receiving FPV or FPV/RTV in Study APV3005 having participated in Study APV30003 or other studies. The PI-naïve and PI-experienced populations (other studies) had received antiretroviral therapy prior to Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>FPV/RTV QD Population (APV30003)</title>
            <description>FPV +/- RTV + background regimen in participants who had received FPV/RTV QD in APV30003 (no NCT number)</description>
          </group>
          <group group_id="O2">
            <title>FPV/RTV BID Population (APV30003)</title>
            <description>FPV +/- RTV + background regimen in participants who had received FPV/RTV BID in APV30003</description>
          </group>
          <group group_id="O3">
            <title>PI-Naïve Population (Other Studies)</title>
            <description>FPV +/- RTV + background regimen in participants who were PI-naïve prior to enrollment in the parent study</description>
          </group>
          <group group_id="O4">
            <title>PI-Experienced Population (Other Studies)</title>
            <description>FPV +/- RTV + background regimen in participants who were PI-experienced prior to enrollment in the parent study</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Plasma HIV-1RNA &lt;400 and &lt;50 Copies Per Milliliter at Baseline and Weeks 12, 24, 48, 60, 96, and 132 (MD=F and Observed)</title>
          <description>Blood samples of participants were collected for the assessment of HIV-1RNA copies in plasma. Viral load, measured in RNA copies per milliliter of plasma, is an efficacy measure for antiretroviral drugs. In the MD=F analysis, participants who had missing data at or had discontinued the study prior to a certain time point are classified as non-responders. In the observed analysis (OA), data are presented for the number of participants still enrolled in the study at a certain time point.</description>
          <population>All participants receiving FPV or FPV/RTV in Study APV3005 having participated in Study APV30003 or other studies. The PI-naïve and PI-experienced populations (other studies) had received antiretroviral therapy prior to Baseline.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="104"/>
                <count group_id="O4" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline &lt;400 copies, n=73, 78, 104, 86; MD=F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="84"/>
                    <measurement group_id="O4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 &lt;400 copies, n=73, 78, 104, 86; MD=F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="82"/>
                    <measurement group_id="O4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 &lt;400 copies, n=73, 78, 104, 86; MD=F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="85"/>
                    <measurement group_id="O4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 &lt;400 copies, n=73, 78, 104, 86; MD=F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="78"/>
                    <measurement group_id="O3" value="78"/>
                    <measurement group_id="O4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60 &lt;400 copies, n=73, 78, 104, 86; MD=F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="77"/>
                    <measurement group_id="O3" value="74"/>
                    <measurement group_id="O4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 &lt;400 copies, n=73, 78, 104, 86; MD=F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="67"/>
                    <measurement group_id="O4" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 132 &lt;400 copies, n=73, 78, 104, 86; MD=F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="60"/>
                    <measurement group_id="O4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline &lt;400 copies, n=73, 78, 92, 82; observed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="95"/>
                    <measurement group_id="O4" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 &lt;400 copies, n=69, 78, 92, 79; observed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="92"/>
                    <measurement group_id="O4" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 &lt;400 copies, n=73, 75, 93, 79; observed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="95"/>
                    <measurement group_id="O4" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 &lt;400 copies, n=73, 77, 85, 68; observed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="95"/>
                    <measurement group_id="O4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60 &lt;400 copies, n=71, 76, 81, 58; observed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="95"/>
                    <measurement group_id="O4" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 &lt;400 copies, n=60, 62, 75, 51; observed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="77"/>
                    <measurement group_id="O3" value="93"/>
                    <measurement group_id="O4" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 132 &lt;400 copies,n=50, 58, 65, 46; observed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="81"/>
                    <measurement group_id="O3" value="95"/>
                    <measurement group_id="O4" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline &lt;50 copies, n=73, 78, 104, 86; MD=F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="59"/>
                    <measurement group_id="O4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 &lt;50 copies, n=73, 78, 104, 86; MD=F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="78"/>
                    <measurement group_id="O4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 &lt;50 copies, n=73, 78, 104, 86; MD=F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="78"/>
                    <measurement group_id="O4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 &lt;50 copies, n=73, 78, 104, 86; MD=F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="69"/>
                    <measurement group_id="O4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60 &lt;50 copies, n=73, 78, 104, 86; MD=F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="68"/>
                    <measurement group_id="O4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 &lt;50 copies, n=73, 78, 104, 86; MD=F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 132 &lt;50 copies, n=73, 78, 104, 86; MD=F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline &lt;50 copies, n=73, 78, 92, 82; observed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="66"/>
                    <measurement group_id="O4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 &lt;50 copies, n=69, 78, 92, 79; observed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="88"/>
                    <measurement group_id="O4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 &lt;50 copies, n=73, 75, 93, 79; observed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="87"/>
                    <measurement group_id="O4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 &lt;50 copies, n=73, 77, 85, 68; observed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="85"/>
                    <measurement group_id="O4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60 &lt;50 copies, n=71, 76, 81, 58; observed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="88"/>
                    <measurement group_id="O4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 &lt;50 copies, n=60, 62, 75, 51; observed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="84"/>
                    <measurement group_id="O4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 132 &lt;50 copies, n=50, 58, 65, 46; observed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="85"/>
                    <measurement group_id="O4" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Plasma HIV-1RNA &lt;50 Copies Per Milliliter at Baseline and Weeks 120, 180, 240, 300, 360, 420, and 432 (Observed)</title>
        <description>Blood samples of participants were collected for the assessment of HIV-1RNA copies in plasma. Viral load, measured in RNA copies per milliliter of plasma,is an efficacy measure for antiretroviral drugs.</description>
        <time_frame>Baseline and Weeks 120, 180, 240, 300, 360, 420, and 432</time_frame>
        <population>All participants who remained in the study after January 31, 2006. Only those participants contributing data at the indicated time points were analyzed. In the observed analysis, data are presented for the number of participants still enrolled in the study who are classified as responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Final Analysis Population (APV30005)</title>
            <description>FPV +/- RTV + background regimen in participants who remained in APV30005 after 31 January 2006</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Plasma HIV-1RNA &lt;50 Copies Per Milliliter at Baseline and Weeks 120, 180, 240, 300, 360, 420, and 432 (Observed)</title>
          <description>Blood samples of participants were collected for the assessment of HIV-1RNA copies in plasma. Viral load, measured in RNA copies per milliliter of plasma,is an efficacy measure for antiretroviral drugs.</description>
          <population>All participants who remained in the study after January 31, 2006. Only those participants contributing data at the indicated time points were analyzed. In the observed analysis, data are presented for the number of participants still enrolled in the study who are classified as responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 120 &lt;50 copies, n=14; observed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 180 &lt;50 copies, n=14; observed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240 &lt;50 copies, n=101; observed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 300 &lt;50 copies, n=82; observed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 360 &lt;50 copies, n=53; observed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 420 &lt;50 copies, n=52; observed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 432 &lt;50 copies, n=41; observed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cluster of Differentiation Antigen 4 (CD4+) Cell Count at Baseline and Weeks 48, 120, 168, 180, 204, and 216: Observed Analysis</title>
        <description>Blood samples of participants were collected for the assessment of CD4+ cell count. CD4+ cells are white blood cells that are important in fighting infection. HIV infects CD4+ cells, replicates in them, and destroys them. CD4+ cell count provides a measure of the status of the immune system and to what extent it is affected by HIV.</description>
        <time_frame>Baseline and Weeks 48, 120, 168, 180, 204, and 216</time_frame>
        <population>All participants receiving FPV or FPV/RTV in Study APV30005 having previously participated in Study APV30001 or Study APV30002. Only those participants contributing data at the indicated time points were analyzed. Participants in the NFV populations had received antiretroviral therapy prior to Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>FPV Population (APV30001)</title>
            <description>FPV +/- RTV + background regimen in participants who had received FPV in APV30001 (NCT00008554)</description>
          </group>
          <group group_id="O2">
            <title>NFV Population (APV30001)</title>
            <description>FPV +/- RTV + background regimen in participants who had received NFV in APV30001</description>
          </group>
          <group group_id="O3">
            <title>FPV Population (APV30002)</title>
            <description>FPV +/- RTV + background regimen in participants who had received FPV in APV30002 (NCT00009061)</description>
          </group>
          <group group_id="O4">
            <title>NFV Population (APV30002)</title>
            <description>FPV +/- RTV + background regimen in participants who had received NFV in APV30002</description>
          </group>
        </group_list>
        <measure>
          <title>Cluster of Differentiation Antigen 4 (CD4+) Cell Count at Baseline and Weeks 48, 120, 168, 180, 204, and 216: Observed Analysis</title>
          <description>Blood samples of participants were collected for the assessment of CD4+ cell count. CD4+ cells are white blood cells that are important in fighting infection. HIV infects CD4+ cells, replicates in them, and destroys them. CD4+ cell count provides a measure of the status of the immune system and to what extent it is affected by HIV.</description>
          <population>All participants receiving FPV or FPV/RTV in Study APV30005 having previously participated in Study APV30001 or Study APV30002. Only those participants contributing data at the indicated time points were analyzed. Participants in the NFV populations had received antiretroviral therapy prior to Baseline.</population>
          <units>cells per millimeters cubed (cells/mm^3)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="219"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, n=119, 18, 219, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="211" lower_limit="2" upper_limit="1136"/>
                    <measurement group_id="O2" value="505" lower_limit="179" upper_limit="1788"/>
                    <measurement group_id="O3" value="167" lower_limit="1" upper_limit="813"/>
                    <measurement group_id="O4" value="297" lower_limit="5" upper_limit="755"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, n=117, 17, 211, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="426" lower_limit="40" upper_limit="1326"/>
                    <measurement group_id="O2" value="499" lower_limit="179" upper_limit="1367"/>
                    <measurement group_id="O3" value="396" lower_limit="58" upper_limit="1188"/>
                    <measurement group_id="O4" value="377" lower_limit="13" upper_limit="884"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120, n=95, 15, 177, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="512" lower_limit="116" upper_limit="1289"/>
                    <measurement group_id="O2" value="613" lower_limit="274" upper_limit="1406"/>
                    <measurement group_id="O3" value="475" lower_limit="90" upper_limit="1595"/>
                    <measurement group_id="O4" value="439" lower_limit="124" upper_limit="888"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168, n=81, 12, 160, 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="594" lower_limit="147" upper_limit="1534"/>
                    <measurement group_id="O2" value="608" lower_limit="287" upper_limit="1069"/>
                    <measurement group_id="O3" value="506" lower_limit="67" upper_limit="1299"/>
                    <measurement group_id="O4" value="422" lower_limit="83" upper_limit="835"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 180, n=78, 9, 153, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="541" lower_limit="418" upper_limit="765"/>
                    <measurement group_id="O2" value="447" lower_limit="180" upper_limit="768"/>
                    <measurement group_id="O3" value="494" lower_limit="113" upper_limit="1261"/>
                    <measurement group_id="O4" value="413" lower_limit="129" upper_limit="970"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 204, n=75, 11, 145, 27</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="535" lower_limit="377" upper_limit="709"/>
                    <measurement group_id="O2" value="563" lower_limit="226" upper_limit="998"/>
                    <measurement group_id="O3" value="494" lower_limit="110" upper_limit="1420"/>
                    <measurement group_id="O4" value="459" lower_limit="115" upper_limit="911"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 216, n=77, 0, 138, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="608" lower_limit="477" upper_limit="846"/>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this arm at this time point.</measurement>
                    <measurement group_id="O3" value="534" lower_limit="117" upper_limit="1687"/>
                    <measurement group_id="O4" value="548" lower_limit="102" upper_limit="641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cluster of Differentiation Antigen 4 (CD4+) Cell Count at Baseline and Weeks 24, 48, 96, 132, and 168: Observed Analysis</title>
        <description>Blood samples of participants were collected for the assessment of CD4+ cell count. CD4+ cells are white blood cells that are important in fighting infection. HIV infects CD4+ cells, replicates in them, and destroys them. CD4+ cell count provides a measure of the status of the immune system and to what extent it is affected by HIV.</description>
        <time_frame>Baseline and Weeks 24, 48, 96, 132, and 168</time_frame>
        <population>All participants receiving FPV or FPV/RTV in Study APV30005 having previously participated in Study APV30003 and other studies. Only those participants contributing data at the indicated time points were analyzed. The PI-naїve and PI-experienced populations (other studies) had received antiretroviral therapy prior to Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>FPV/RTV QD Population (APV30003)</title>
            <description>FPV +/- RTV + background regimen in participants who had received FPV/RTV QD in APV30003 (no NCT number)</description>
          </group>
          <group group_id="O2">
            <title>FPV/RTV BID Population (APV30003)</title>
            <description>FPV +/- RTV + background regimen in participants who had received FPV/RTV BID in APV30003</description>
          </group>
          <group group_id="O3">
            <title>PI-Naïve Population (Other Studies)</title>
            <description>FFPV +/- RTV + background regimen in participants who were PI-naïve prior to enrollment in the parent study</description>
          </group>
          <group group_id="O4">
            <title>PI-Experienced Population (Other Studies)</title>
            <description>FPV +/- RTV + background regimen in participants who were PI-experienced prior to enrollment in the parent study</description>
          </group>
        </group_list>
        <measure>
          <title>Cluster of Differentiation Antigen 4 (CD4+) Cell Count at Baseline and Weeks 24, 48, 96, 132, and 168: Observed Analysis</title>
          <description>Blood samples of participants were collected for the assessment of CD4+ cell count. CD4+ cells are white blood cells that are important in fighting infection. HIV infects CD4+ cells, replicates in them, and destroys them. CD4+ cell count provides a measure of the status of the immune system and to what extent it is affected by HIV.</description>
          <population>All participants receiving FPV or FPV/RTV in Study APV30005 having previously participated in Study APV30003 and other studies. Only those participants contributing data at the indicated time points were analyzed. The PI-naїve and PI-experienced populations (other studies) had received antiretroviral therapy prior to Baseline.</population>
          <units>cells per millimeters cubed (cells/mm^3)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="94"/>
                <count group_id="O4" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, n=72, 78, 94, 76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="311" lower_limit="6" upper_limit="1171"/>
                    <measurement group_id="O2" value="304" lower_limit="41" upper_limit="845"/>
                    <measurement group_id="O3" value="477" lower_limit="130" upper_limit="1224"/>
                    <measurement group_id="O4" value="361" lower_limit="6" upper_limit="1354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, n=71, 73, 92, 75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="367" lower_limit="69" upper_limit="1391"/>
                    <measurement group_id="O2" value="348" lower_limit="101" upper_limit="1051"/>
                    <measurement group_id="O3" value="520" lower_limit="128" upper_limit="1266"/>
                    <measurement group_id="O4" value="399" lower_limit="28" upper_limit="1120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, n=73, 77, 85, 68</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="374" lower_limit="66" upper_limit="914"/>
                    <measurement group_id="O2" value="386" lower_limit="99" upper_limit="965"/>
                    <measurement group_id="O3" value="582" lower_limit="42" upper_limit="1194"/>
                    <measurement group_id="O4" value="418" lower_limit="10" upper_limit="1121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96, n=58, 62, 73, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="409" lower_limit="179" upper_limit="868"/>
                    <measurement group_id="O2" value="417" lower_limit="82" upper_limit="744"/>
                    <measurement group_id="O3" value="567" lower_limit="82" upper_limit="1342"/>
                    <measurement group_id="O4" value="463" lower_limit="21" upper_limit="929"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 132, n=50, 56, 64, 47</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="395" lower_limit="120" upper_limit="1015"/>
                    <measurement group_id="O2" value="386" lower_limit="38" upper_limit="820"/>
                    <measurement group_id="O3" value="642" lower_limit="159" upper_limit="1193"/>
                    <measurement group_id="O4" value="486" lower_limit="16" upper_limit="1769"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168, n=40, 47, 20, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="513" lower_limit="133" upper_limit="1069"/>
                    <measurement group_id="O2" value="409" lower_limit="59" upper_limit="1097"/>
                    <measurement group_id="O3" value="619" lower_limit="260" upper_limit="1312"/>
                    <measurement group_id="O4" value="460" lower_limit="51" upper_limit="890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Plasma HIV-1 RNA at Baseline and Weeks 24, 48, 72, 96, 120, 144, 168, 180, 204, and 216</title>
        <description>Blood samples of participants were collected for the assessment of plasma HIV-1 RNA.</description>
        <time_frame>Baseline and Weeks 24, 48, 72, 96, 120, 144, 168, 180, 204, and 216</time_frame>
        <population>All participants receiving FPV or FPV/RTV in Study APV30005 having previously particpated in Study APV30001 or Study APV30002. Only those participants contributing data at the indicated time points were analyzed. Participants in the NFV populations had received antiretroviral therapy prior to Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>FPV Population (APV30001)</title>
            <description>FPV +/- RTV + background regimen in participants who had received FPV in APV30001 (NCT00008554)</description>
          </group>
          <group group_id="O2">
            <title>NFV Population (APV30001)</title>
            <description>FPV +/- RTV + background regimen in participants who had received NFV in APV30001</description>
          </group>
          <group group_id="O3">
            <title>FPV Population (APV30002)</title>
            <description>FPV +/- RTV + background regimen in participants who had received FPV in APV30002 (NCT00009061)</description>
          </group>
          <group group_id="O4">
            <title>NFV Population (APV30002)</title>
            <description>FPV +/- RTV + background regimen in participants who had received NFV in APV30002</description>
          </group>
        </group_list>
        <measure>
          <title>Median Plasma HIV-1 RNA at Baseline and Weeks 24, 48, 72, 96, 120, 144, 168, 180, 204, and 216</title>
          <description>Blood samples of participants were collected for the assessment of plasma HIV-1 RNA.</description>
          <population>All participants receiving FPV or FPV/RTV in Study APV30005 having previously particpated in Study APV30001 or Study APV30002. Only those participants contributing data at the indicated time points were analyzed. Participants in the NFV populations had received antiretroviral therapy prior to Baseline.</population>
          <units>log 10 copies per milliliter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="221"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, n=119, 18, 221, 54</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.82" lower_limit="1.69" upper_limit="7.4"/>
                    <measurement group_id="O2" value="1.69" lower_limit="1.69" upper_limit="5.6"/>
                    <measurement group_id="O3" value="4.82" lower_limit="2.65" upper_limit="7.29"/>
                    <measurement group_id="O4" value="1.78" lower_limit="1.69" upper_limit="5.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, n=119, 17, 217, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" lower_limit="1.69" upper_limit="5.8"/>
                    <measurement group_id="O2" value="1.69" lower_limit="1.69" upper_limit="5.7"/>
                    <measurement group_id="O3" value="1.69" lower_limit="1.69" upper_limit="5.49"/>
                    <measurement group_id="O4" value="1.69" lower_limit="1.69" upper_limit="5.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, n=118, 17, 218, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" lower_limit="1.69" upper_limit="5.9"/>
                    <measurement group_id="O2" value="1.69" lower_limit="1.69" upper_limit="5.4"/>
                    <measurement group_id="O3" value="1.69" lower_limit="1.69" upper_limit="5.03"/>
                    <measurement group_id="O4" value="1.69" lower_limit="1.69" upper_limit="4.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72, n=113, 15, 204, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" lower_limit="1.69" upper_limit="4.8"/>
                    <measurement group_id="O2" value="1.69" lower_limit="1.69" upper_limit="3.5"/>
                    <measurement group_id="O3" value="1.69" lower_limit="1.69" upper_limit="5.83"/>
                    <measurement group_id="O4" value="1.69" lower_limit="1.69" upper_limit="5.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96, n=106, 15, 192, 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" lower_limit="1.69" upper_limit="4.7"/>
                    <measurement group_id="O2" value="1.69" lower_limit="1.69" upper_limit="3.6"/>
                    <measurement group_id="O3" value="1.69" lower_limit="1.69" upper_limit="5.38"/>
                    <measurement group_id="O4" value="1.69" lower_limit="1.69" upper_limit="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120, n=96, 15, 183, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" lower_limit="1.69" upper_limit="4.9"/>
                    <measurement group_id="O2" value="1.69" lower_limit="1.69" upper_limit="3.1"/>
                    <measurement group_id="O3" value="1.69" lower_limit="1.69" upper_limit="5.53"/>
                    <measurement group_id="O4" value="1.69" lower_limit="1.69" upper_limit="3.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144, n=89, 15, 173, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" lower_limit="1.69" upper_limit="4.2"/>
                    <measurement group_id="O2" value="1.69" lower_limit="1.69" upper_limit="3.9"/>
                    <measurement group_id="O3" value="1.69" lower_limit="1.69" upper_limit="5.38"/>
                    <measurement group_id="O4" value="1.69" lower_limit="1.69" upper_limit="3.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168, n=81, 14, 160, 38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" lower_limit="1.69" upper_limit="4.8"/>
                    <measurement group_id="O2" value="1.69" lower_limit="1.69" upper_limit="4.0"/>
                    <measurement group_id="O3" value="1.69" lower_limit="1.69" upper_limit="5.44"/>
                    <measurement group_id="O4" value="1.69" lower_limit="1.69" upper_limit="4.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 180, n=82, 12, 159, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" lower_limit="1.69" upper_limit="4.7"/>
                    <measurement group_id="O2" value="1.69" lower_limit="1.69" upper_limit="3.3"/>
                    <measurement group_id="O3" value="1.69" lower_limit="1.69" upper_limit="4.71"/>
                    <measurement group_id="O4" value="1.69" lower_limit="1.69" upper_limit="3.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 204, n=78, 12, 153, 27</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" lower_limit="1.69" upper_limit="3.8"/>
                    <measurement group_id="O2" value="1.69" lower_limit="1.69" upper_limit="3.5"/>
                    <measurement group_id="O3" value="1.69" lower_limit="1.69" upper_limit="5.26"/>
                    <measurement group_id="O4" value="1.69" lower_limit="1.69" upper_limit="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 216, n=80, 0, 143, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" lower_limit="1.69" upper_limit="5.4"/>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this arm at this time point.</measurement>
                    <measurement group_id="O3" value="1.69" lower_limit="1.69" upper_limit="5.59"/>
                    <measurement group_id="O4" value="1.69" lower_limit="1.69" upper_limit="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Plasma HIV-1 RNA at Baseline and Weeks 12, 24, 48, 72, 96, 132, and 168</title>
        <description>Blood samples of participants were collected for the assessment of plasma HIV-1 RNA.</description>
        <time_frame>Baseline and Weeks 12, 24, 48, 72, 96, 132, and 168</time_frame>
        <population>All participants receiving FPV or FPV/RTV in Study APV30005 having previously participated in Study APV30003 or other studies. Only those participants contributing data at the indicated time points were analyzed. The PI naïve and PI-experienced populations (other studies) had received antiretroviral therapy prior to Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>FPV/RTV QD Population (APV30003)</title>
            <description>FPV +/- RTV + background regimen in participants who had received FPV/RTV QD in APV30003 (no NCT number)</description>
          </group>
          <group group_id="O2">
            <title>FPV/RTV BID Population (APV30003)</title>
            <description>FPV +/- RTV + background regimen in participants who had received FPV/RTV BID in APV30003</description>
          </group>
          <group group_id="O3">
            <title>PI-Naïve Population (Other Studies)</title>
            <description>FPV +/- RTV + background regimen in participants who were PI-naïve prior to enrollment in the parent study</description>
          </group>
          <group group_id="O4">
            <title>PI-Experienced Population (Other Studies)</title>
            <description>FPV +/- RTV + background regimen in participants who were PI-experienced prior to enrollment in the parent study</description>
          </group>
        </group_list>
        <measure>
          <title>Median Plasma HIV-1 RNA at Baseline and Weeks 12, 24, 48, 72, 96, 132, and 168</title>
          <description>Blood samples of participants were collected for the assessment of plasma HIV-1 RNA.</description>
          <population>All participants receiving FPV or FPV/RTV in Study APV30005 having previously participated in Study APV30003 or other studies. Only those participants contributing data at the indicated time points were analyzed. The PI naïve and PI-experienced populations (other studies) had received antiretroviral therapy prior to Baseline.</population>
          <units>log 10 copies per milliliter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, n=73, 78, 92, 82</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.96" lower_limit="3.0" upper_limit="5.8"/>
                    <measurement group_id="O2" value="4.06" lower_limit="2.3" upper_limit="5.9"/>
                    <measurement group_id="O3" value="1.7" lower_limit="1.7" upper_limit="4.9"/>
                    <measurement group_id="O4" value="1.81" lower_limit="1.7" upper_limit="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, n=69, 78, 92, 79</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.7" upper_limit="5.3"/>
                    <measurement group_id="O2" value="1.81" lower_limit="1.7" upper_limit="5.8"/>
                    <measurement group_id="O3" value="1.7" lower_limit="1.7" upper_limit="6.0"/>
                    <measurement group_id="O4" value="2.03" lower_limit="1.7" upper_limit="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, n=73, 75, 93, 79</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" lower_limit="1.69" upper_limit="4.8"/>
                    <measurement group_id="O2" value="1.69" lower_limit="1.69" upper_limit="5.6"/>
                    <measurement group_id="O3" value="1.7" lower_limit="1.7" upper_limit="5.5"/>
                    <measurement group_id="O4" value="1.9" lower_limit="1.7" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, n=73, 77, 85, 68</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" lower_limit="1.7" upper_limit="4.5"/>
                    <measurement group_id="O2" value="1.69" lower_limit="1.69" upper_limit="5.8"/>
                    <measurement group_id="O3" value="1.7" lower_limit="1.7" upper_limit="5.3"/>
                    <measurement group_id="O4" value="1.7" lower_limit="1.7" upper_limit="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72, n=65, 73, 80, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" lower_limit="1.7" upper_limit="5.5"/>
                    <measurement group_id="O2" value="1.69" lower_limit="1.69" upper_limit="5.4"/>
                    <measurement group_id="O3" value="1.7" lower_limit="1.7" upper_limit="4.7"/>
                    <measurement group_id="O4" value="1.7" lower_limit="1.7" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96, n=60, 62, 75, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" lower_limit="1.69" upper_limit="4.9"/>
                    <measurement group_id="O2" value="1.69" lower_limit="1.69" upper_limit="5.2"/>
                    <measurement group_id="O3" value="1.7" lower_limit="1.7" upper_limit="5.4"/>
                    <measurement group_id="O4" value="1.7" lower_limit="1.7" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 132, n=50, 58, 65, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" lower_limit="1.69" upper_limit="4.8"/>
                    <measurement group_id="O2" value="1.69" lower_limit="1.69" upper_limit="5.8"/>
                    <measurement group_id="O3" value="1.7" lower_limit="1.7" upper_limit="4.0"/>
                    <measurement group_id="O4" value="1.7" lower_limit="1.7" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168, n=44, 48, 20, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" lower_limit="1.69" upper_limit="4.8"/>
                    <measurement group_id="O2" value="1.69" lower_limit="1.69" upper_limit="4.9"/>
                    <measurement group_id="O3" value="1.7" lower_limit="1.7" upper_limit="2.8"/>
                    <measurement group_id="O4" value="1.7" lower_limit="1.7" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Plasma HIV-1 RNA at Weeks 180, 240, 300, 360, 420, and 432</title>
        <description>Blood samples of participants were collected for the assessment of plasma HIV-1 RNA.</description>
        <time_frame>Weeks 180, 240, 300, 360, 420, and 432</time_frame>
        <population>All participants who remained in the study after January 31, 2006. Only those participants contributing data at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Final Analysis Population (APV30005)</title>
            <description>FPV +/- RTV + background regimen in participants who remained in APV30005 after 31 January 2006</description>
          </group>
        </group_list>
        <measure>
          <title>Median Plasma HIV-1 RNA at Weeks 180, 240, 300, 360, 420, and 432</title>
          <description>Blood samples of participants were collected for the assessment of plasma HIV-1 RNA.</description>
          <population>All participants who remained in the study after January 31, 2006. Only those participants contributing data at the indicated time points were analyzed.</population>
          <units>log 10 copies per milliliters</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 180, n=14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.7" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240, n=101</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.7" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 300, n=82</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.7" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 360, n=53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.7" upper_limit="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 420, n=52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.7" upper_limit="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 432, n=41</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.7" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With HIV-1 Disease Progression to CDC Class C, or New CDC Class C or Death, From Baseline</title>
        <description>The number of participants with progression of HIV-1 disease were assessed using the CDC classification of HIV-1: class A, asymptomatic or lymphadenopathy; class B: symptomatic, but not AIDS; class C, AIDS. A participant is considered to have had a disease progression if they report a CDC Class C event for the first time, if they report a new CDC Class C event, or if they experience any fatal adverse event during the study.</description>
        <time_frame>Baseline (Day 1) up to 31 January 2006 (up to Week 264)</time_frame>
        <population>All participants receiving at least one dose of FPV or FPV/RTV in Study APV30005.</population>
        <group_list>
          <group group_id="O1">
            <title>FPV Population (APV30001)</title>
            <description>FPV +/- RTV + background regimen in participants who had received FPV in APV30001 (NCT00008554)</description>
          </group>
          <group group_id="O2">
            <title>NFV Population (APV30001)</title>
            <description>FPV +/- RTV + background regimen in participants who had received NFV in APV30001</description>
          </group>
          <group group_id="O3">
            <title>FPV Population (APV30002)</title>
            <description>FPV +/- RTV + background regimen in participants who had received FPV in APV30002 (NCT00009061)</description>
          </group>
          <group group_id="O4">
            <title>NFV Population (APV30002)</title>
            <description>FPV +/- RTV + background regimen in participants who had received NFV in APV30002</description>
          </group>
          <group group_id="O5">
            <title>FPV/RTV QD Population (APV30003)</title>
            <description>FPV +/- RTV + background regimen in participants who had received FPV/RTV QD in APV30003 (no NCT number)</description>
          </group>
          <group group_id="O6">
            <title>FPV/RTV BID Population (APV30003)</title>
            <description>FPV +/- RTV + background regimen in participants who had received FPV/RTV BID in APV30003</description>
          </group>
          <group group_id="O7">
            <title>PI-Naïve Population (Other Studies)</title>
            <description>FPV +/- RTV + background regimen in participants who were PI-naïve prior to enrollment in the parent study</description>
          </group>
          <group group_id="O8">
            <title>PI-Experienced Population (Other Studies)</title>
            <description>FPV +/- RTV + background regimen in participants who were PI-experienced prior to enrollment in the parent study</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HIV-1 Disease Progression to CDC Class C, or New CDC Class C or Death, From Baseline</title>
          <description>The number of participants with progression of HIV-1 disease were assessed using the CDC classification of HIV-1: class A, asymptomatic or lymphadenopathy; class B: symptomatic, but not AIDS; class C, AIDS. A participant is considered to have had a disease progression if they report a CDC Class C event for the first time, if they report a new CDC Class C event, or if they experience any fatal adverse event during the study.</description>
          <population>All participants receiving at least one dose of FPV or FPV/RTV in Study APV30005.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="221"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="73"/>
                <count group_id="O6" value="78"/>
                <count group_id="O7" value="104"/>
                <count group_id="O8" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CDC class A to CDC class C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDC class B to CDC class C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDC class C to new CDC class C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDC class A, B, or C to death (on treatment)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Enrolled in Studies APV30001 and APV300002 With the Indicated HIV-associated Conditions</title>
        <description>The number of participants with the indicated HIV-associated conditions were assessed, excluding recurrences.</description>
        <time_frame>Baseline (Day 1) up to 31 January 2006 (up to Week 264)</time_frame>
        <population>All participants receiving FPV or NFV in Studies APV30001 and APV30002.</population>
        <group_list>
          <group group_id="O1">
            <title>FPV Population (APV30001)</title>
            <description>FPV +/- RTV + background regimen in participants who had received FPV in APV30001 (NCT00008554)</description>
          </group>
          <group group_id="O2">
            <title>NFV Population (APV30001)</title>
            <description>FPV +/- RTV + background regimen in participants who had received NFV in APV30001</description>
          </group>
          <group group_id="O3">
            <title>FPV Population (APV30002)</title>
            <description>FPV +/- RTV + background regimen in participants who had received FPV in APV30002 (NCT00009061)</description>
          </group>
          <group group_id="O4">
            <title>NFV Population (APV30002)</title>
            <description>FPV +/- RTV + background regimen in participants who had received NFV in APV30002</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Enrolled in Studies APV30001 and APV300002 With the Indicated HIV-associated Conditions</title>
          <description>The number of participants with the indicated HIV-associated conditions were assessed, excluding recurrences.</description>
          <population>All participants receiving FPV or NFV in Studies APV30001 and APV30002.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="221"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Candidiasis, oropharyngeal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Herpes zoster</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea lasting &gt;1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Candidiasis, vulvovaginal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cervical dysplasia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever lasting &gt;1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hairy leukoplakia, oral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral neuropathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cytomegalovirus retinitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Herpes simplex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mycobacterium tuberculosis, any site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Encepathopathy, HIV-related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kaposis's sarcoma, cutaneous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphoma,immunoblastic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mycobacterium avium complex/ M kansaii</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumocystis carinii pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive multifocal leukoencephalopathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxoplasmosis of brain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-CDC HIV-associated conditions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Enrolled in Study APV30003 and Other Studies With the Indicated HIV-associated Conditions</title>
        <description>The number of participants with the indicated HIV-associated conditions were assessed.</description>
        <time_frame>Baseline (Day 1) up to 31 January 2006 (up to Week 264)</time_frame>
        <population>All participants receiving FPV/RTV in Study APV30005 having previously participated in Study APV30003 or other studies.</population>
        <group_list>
          <group group_id="O1">
            <title>FPV/RTV QD Population (APV30003)</title>
            <description>FPV +/- RTV + background regimen in participants who had received FPV/RTV QD in APV30003 (no NCT number)</description>
          </group>
          <group group_id="O2">
            <title>FPV/RTV BID Population (APV30003)</title>
            <description>FPV +/- RTV + background regimen in participants who had received FPV/RTV BID in APV30003</description>
          </group>
          <group group_id="O3">
            <title>PI-Naïve Population (Other Studies)</title>
            <description>FPV +/- RTV + background regimen in participants who were PI-naïve prior to enrollment in the parent study</description>
          </group>
          <group group_id="O4">
            <title>PI-Experienced Population (Other Studies)</title>
            <description>FPV +/- RTV + background regimen in participants who were PI-experienced prior to enrollment in the parent study</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Enrolled in Study APV30003 and Other Studies With the Indicated HIV-associated Conditions</title>
          <description>The number of participants with the indicated HIV-associated conditions were assessed.</description>
          <population>All participants receiving FPV/RTV in Study APV30005 having previously participated in Study APV30003 or other studies.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="104"/>
                <count group_id="O4" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Candidiasis, oropharyngeal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hairy leukoplakia, oral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral neuropathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea lasting &gt;1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Herpes Zoster</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mycobacterium tuberculosis, any site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other, Non-CDC HIV associated condition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>FPV Population (APV30001)</title>
          <description>FPV +/- RTV + background regimen in participants who had received FPV in APV30001 (NCT00008554)</description>
        </group>
        <group group_id="E2">
          <title>NFV Population (APV30001)</title>
          <description>FPV +/- RTV + background regimen in participants who had received NFV in APV30001</description>
        </group>
        <group group_id="E3">
          <title>FPV Population (APV30002)</title>
          <description>FPV +/- RTV + background regimen in participants who had received FPV in APV30002 (NCT00009061)</description>
        </group>
        <group group_id="E4">
          <title>NFV Population (APV30002)</title>
          <description>FPV +/- RTV + background regimen in participants who had received NFV in APV30002</description>
        </group>
        <group group_id="E5">
          <title>FPV/RTV QD Population (APV30003)</title>
          <description>FPV +/- RTV + background regimen in participants who had received FPV/RTV QD in APV30003 (no NCT number)</description>
        </group>
        <group group_id="E6">
          <title>FPV/RTV BID Population (APV30003)</title>
          <description>FPV +/- RTV + background regimen in participants who had received FPV/RTV BID in APV30003</description>
        </group>
        <group group_id="E7">
          <title>PI-Naïve Population (Other Studies)</title>
          <description>FPV +/- RTV + background regimen in participants who were PI-naïve prior to enrollment in the parent study</description>
        </group>
        <group group_id="E8">
          <title>PI-Experienced Population (Other Studies)</title>
          <description>FPV +/- RTV + background regimen in participants who were PI-experienced prior to enrollment in the parent study</description>
        </group>
        <group group_id="E9">
          <title>Final Analysis Population (APV30005)</title>
          <description>FPV +/- RTV + background regimen in participants who remained in APV30005 after 31 January 2006</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="15" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Pterygium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Anal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Cellulitis of male external genital organ</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pneumocystis jiroveci pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Scrotal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Syphilis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pneumonia primary atypical</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Superinfection lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Leishmaniasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Perianal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Visceral leishmaniasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Urinary tract infection pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Gastrointestinal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Anastomotic leak</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Collapse of lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Laryngeal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Penis carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Post herpetic neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Schizoaffective disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Conversion disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Depression suicidal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Mood altered</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Urethral disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Fibrocystic breast disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Breast enlargement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="209" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="53" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="68" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="73" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="76" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="40" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="82" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="131" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="37" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="14" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="14" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="100" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="69" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="21" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="32" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="14" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="23" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="12" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Parasitic infection intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Vaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Vulvovaginitis trichomonal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Sexual transmission of infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Syphilis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Torticollis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="12" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="28" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Hypoasthesia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Lipodystrophy acquired</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Dermititis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="11" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="221"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>ViiV Healthcare</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

